

European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm Society (LAHRS)

Bulent Gorenk (Chair)^{1*}, Giuseppe Boriani², Gheorge-Andrei Dan³, Laurent Fauchier⁴, Guilherme Fenelon⁵, He Huang⁶, Gulmira Kudaiberdieva^{7,8}, Gregory Y.H. Lip^{9,10}, Rajiv Mahajan¹¹, Tatjana Potpara¹², Juan David Ramirez¹³, Marc A. Vos¹⁴, and Francisco Marin (Co-Chair)¹⁵

ESC Scientific Document Group: Carina Blomstrom-Lundqvist¹⁶, Aldo Rinaldi¹⁷, Maria Grazia Bongiorno¹⁸, Elena Sciaraffia¹⁹, Jens Cosedis Nielsen²⁰, Thorsten Lewalter²¹, Shu Zhang²², Oswaldo Gutiérrez²³, Abdel Fuenmayor²⁴

¹Eskisehir Osmangazi University, Eskisehir, Turkey; ²Cardiology Division, Department of Diagnostics, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy; ³University of Medicine and Pharmacy “Carol Davila”, Colentina University Hospital, Bucharest, Romania; ⁴Centre Hospitalier Universitaire Trousseau et Université François Rabelais, Tours, France; ⁵Hospital Israelita Albert Einstein, São Paulo, Brazil; ⁶Renmin Hospital of Wuhan University, Wuhan, China; ⁷Adana, Turkey; ⁸Center for Postgraduate Education and Research, Bishkek, Kyrgyzstan; ⁹Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK; ¹⁰Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; ¹¹The University of Adelaide, Lyell McEwin Hospital, Royal Adelaide Hospital and SAHMR, Adelaide, Australia; ¹²School of Medicine, Belgrade University; Cardiology Clinic, Clinical Centre of Serbia, Belgrade, Serbia; ¹³Clinica CardioVid, Medellín, Antioquia, Colombia; ¹⁴Umc Utrecht, Utrecht, Netherlands; ¹⁵HU Virgen de la Arrixaca, Murcia, Spain; ¹⁶Department of Medical Science and Cardiology, Uppsala University, Uppsala, Sweden; ¹⁷St Thomas’ Hospital, London, UK; ¹⁸Santa Chiara University Hospital of Pisa, Pisa, Italy; ¹⁹Uppsala University Hospital, Uppsala, Sweden; ²⁰Aarhus University Hospital, Aarhus, Denmark; ²¹Peter Osypka Heart Center, Munich, Germany; ²²Beijing Fuwai Hospital, Beijing, China; ²³Hospital Clinica Bblica, San Jose, Costa Rica; and ²⁴Electrophysiology and Arrhythmia Section, Cardiovascular Research Institute, University Hospital of The Andes, Avenida 16 de Septiembre, Mérida 5101, Venezuela

Received 19 February 2018; editorial decision 22 February 2018; accepted 25 February 2018

Endocrine disorders are associated with various tachyarrhythmias, including atrial fibrillation (AF), ventricular tachycardia (VT), ventricular fibrillation (VF), and bradyarrhythmias. Along with underlying arrhythmia substrate, electrolyte disturbances, glucose, and hormone levels, accompanying endocrine disorders contribute to development of arrhythmia. Arrhythmias may be life-threatening, facilitate cardiogenic shock development and increase mortality. The knowledge on the incidence of tachy- and bradyarrhythmias, clinical and prognostic significance as well as their management is limited; it is represented in observational studies and mostly in case reports on management of challenging cases. It should be also emphasized, that the topic is not covered in detail in current guidelines. Therefore, cardiologists and multidisciplinary teams participating in care of such patients do need the evidence-based, or in case of limited evidence expert-opinion based recommendations, how to treat arrhythmias using contemporary approaches, prevent their complications and recurrence in patients with endocrine disorders. In recognizing this close relationship between endocrine disorders and arrhythmias, the European Heart Rhythm Association (EHRA) convened a Task Force, with representation from Asia-Pacific Heart Rhythm Society (APHRS)

* Corresponding author. Tel: +905424312483. E-mail address: bulent@gorenk.com

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018. For permissions, please email: journals.permissions@oup.com.

and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLAECE), with the remit of comprehensively reviewing the available evidence and publishing a joint consensus document on endocrine disorders and cardiac arrhythmias, and providing up-to-date consensus recommendations for use in clinical practice.

Keywords

Endocrine disorders • Arrhythmias • Atrial fibrillation • Ventricular arrhythmias • Cardiac implantable electronic device • Pacemaker • Implantable cardioverter-defibrillator • Catheter ablation • Diabetes • Thyroid disorders • Hyperthyroidism • Hypothyroidism • Pheochromocytoma • Growth hormone dysfunction • Hyperaldosteronism • Adrenal insufficiency • Parathyroid disease • Stroke • Oral anticoagulation • EHRA position paper

Table of Contents

Introduction	2
Evidence review	2
Mechanisms and pathophysiology of cardiac arrhythmias in endocrine disorders	2
Management of arrhythmias in specific endocrine disorders	3
Pancreas dysfunction.....	3
Diabetes mellitus.....	3
Thyroid dysfunction.....	10
Hyperthyroidism.....	10
Hypothyroidism.....	11
Amiodarone-induced thyroid dysfunction	14
Pheochromocytoma.....	18
Growth hormone dysfunction.....	19
Acromegaly.....	19
Growth hormone deficiency.....	19
Diseases of adrenal cortex	20
Hyperaldosteronism	21
Adrenal insufficiency	20
Parathyroid disease.....	21
Sex hormones-related differences in the risk of arrhythmias	21
Stroke risk assessment and prevention of arrhythmias associated with endocrine disorders	22
Catheter ablation of arrhythmias associated with endocrine disorders ..	23
Device-based therapy of arrhythmias in patients with endocrine disorders	23
Current research gaps, ongoing trials and future directions.....	24

Introduction

However, the ultimate judgement on the care of a specific patient must be made by the healthcare provider and the patient in light of all individual factors presented.

Evidence review

This document was prepared by the Task Force with representation from EHRA, APHRS, and SOLAECE and peer-reviewed by official external reviewers representing EHRA, HRS, APHRS, and SOLAECE. Their members made a detailed literature review, weighing the strength of evidence for or against a specific treatment or procedure, and including estimates of expected health outcomes where data exist. In controversial areas, or with respect to issues without evidence other than usual clinical practice, a consensus was achieved by agreement of the expert panel after thorough deliberation.

In contrast to guidelines, we opted for an easier and user-friendly system of ranking using 'coloured hearts' that should allow physicians to easily assess the current status of the evidence and consequent guidance (Table 1). This EHRA grading of consensus statements does not have separate definitions of the level of evidence. This categorization, used for consensus statements, must not be considered as directly similar to that used for official society guideline recommendations, which apply a classification (Class I–III) and level of evidence (A, B, and C) to recommendations used in official guidelines.

Thus, a green heart indicates a 'should do this' consensus statement or indicated treatment or procedure that is based on at least one randomized trial, or is supported by strong observational evidence that it is beneficial and effective. A yellow heart indicates general agreement and/or scientific evidence favouring a 'may do this' statement or the usefulness/efficacy of a treatment or procedure. A 'yellow heart' symbol may be supported by randomized trials based on a small number of patients or which is not widely applicable. Treatment strategies for which there is scientific evidence of potential harm and should not be used ('do not do this') are indicated by a red heart.




Mechanisms and pathophysiology of cardiac arrhythmias in endocrine disorders

A number of cardiac arrhythmia mechanisms may underlie ventricular and atrial arrhythmias, such as reentry, abnormal automaticity or triggered activity. Normally, these mechanisms are not active in a normal (young) heart. The only exceptions are inherited arrhythmia syndromes, in which cardiac remodelling may be present that make the heart more vulnerable often under specific circumstances, like the excess of catecholamines.

Acutely, hormones can play a crucial role such as in catecholamine-induced polymorphic VT, induced by exercise or in the long QT syndrome (LQTS), induced either by sleep, fear, or excitement. Often the challenge provided acutely by these hormones exceeds the safety margins (=reserve) of the vulnerable heart to overcome and ventricular arrhythmias ensue. Thus, endocrine disorders may play an acute role in the triggering of cardiac arrhythmias (Figure 1).

However, there are also chronic adaptations induced by endocrine disorders that can underlie the formation of arrhythmias. The action potential is controlled by numerous ion currents that either provides inward or outward currents. It is this delicate balance that shapes the

Table 1 Scientific rationale of recommendations^a

Definitions where related to a treatment or procedure	Consensus statement instruction	Symbol
Scientific evidence that a treatment or procedure is beneficial and effective. Requires at least one randomized trial or is supported by strong observational evidence and authors' consensus (as indicated by an asterisk)	'Should do this'	
General agreement and/or scientific evidence favour the usefulness/efficacy of a treatment or procedure. May be supported by randomized trials based on a small number of patients or which is not widely applicable	'May do this'	
Scientific evidence or general agreement not to use or recommend a treatment or procedure	'Do not do this'	

^aThis categorization for our consensus document should not be considered as being directly similar to that used for official society guideline recommendations which apply a classification (I–III) and level of evidence (A, B, and C) to recommendations.




Figure 1 Mechanism of arrhythmias in endocrine disorders: The balance between the strength of the heart to de- or repolarize is often challenged by the autonomic nervous system. When the balance is off, the heart has to allow arrhythmias, which can be based upon numerous arrhythmogenic mechanisms. VF, ventricular fibrillation; VT, ventricular tachycardia.

action potential and determines its duration, often measured as QT-duration. Overexpression or down-regulation of these ion currents can chronically increase or decrease conduction or repolarization reserve.

A few examples have been listed:

Diabetes mellitus: In an experimental model, mimicking diabetes type 1, it was demonstrated that this metabolic disorder reduced repolarization reserve by decreasing the outward current 'slowly delayed rectifier (IKs)' in the rabbit, thereby increasing the liability for drug induced Torsade de Pointes.¹ More recently, it has been suggested that the transcription of ion channels due to the involvement of the P13K pathway is responsible for this reduced transcription.²

Gender differences: The incidence and prevalence of AF and sustained ventricular arrhythmias and sudden cardiac death (SCD) are lower in women than in men. However, women have a greater chance to develop Torsade de Pointes arrhythmias.³ It has been shown that sex hormones account for most of the differences in the cardiac electrophysiological properties observed between females and males. Human data demonstrate that the expression of a number of potassium channels is reduced


in females accounting for a prolonged duration of the ventricular action potential.⁴ Testosterone reduces the ventricular action potential duration (APD) by enhancing the slow delayed rectifier current and by increasing the I-type calcium current.⁴

Adrenal dysfunction: Glucocorticoid has been reported to be important for the maintenance of membrane Calcium transport in the cardiac sarcoplasmic reticulum and for the regulation of various ion channels, including IKs, and the rapid delayed rectifier (IKr), thereby manipulating QT duration.⁵

Management of arrhythmias in specific endocrine disorders

Diabetes mellitus

Diabetes mellitus (DM) type 1 (reduced insulin production) or type 2 (increased resistance to insulin) may increase the risk of cardiac arrhythmias via many factors including: (i) cardiovascular risk factors (e.g. hypertension), (ii) atherosclerotic cardiovascular disease [i.e. coronary



artery disease (CAD), prior myocardial infarction (MI), stroke, or peripheral arterial disease],^{6–8} and (iii) DM-associated factors such as glucose control, diabetic neuropathy, or cardiomyopathy (Figure 2).^{6,9,10} The risk for arrhythmias or SCD in DM patients is closely related to the presence and severity of underlying cardiovascular disease,^{6,11–13} but the aforementioned DM-related factors could induce arrhythmias independently of cardiovascular comorbidities. Management of cardiac arrhythmias in DM patients is outlined in Figure 3.

Atrial fibrillation

Many epidemiological studies have reported an association of DM with incident AF.^{14,15} The duration of DM and glycaemic control were also associated with AF (each year with DM conferred a 3% increase in the risk of AF),¹⁶ whilst HbA1c of >9% was associated with a nearly two-fold increase in AF risk.¹⁷ A meta-analysis of 11 studies with a total of 108 703 AF cases in 1 686 097 subjects showed a 40% greater risk of AF in the presence of DM, but the effect was attenuated after adjustment for multiple risk factors [relative risk 1.24, 95% confidence interval (CI) 1.06–1.44], whilst the population-attributable estimate for AF owing to DM was 2.5% (95% CI 0.1–3.9).¹⁸ In several observational studies, the age-adjusted association of DM with incident AF was no longer significant after multiple adjustments for hypertension, cardiovascular comorbidity, body mass index, or obesity,^{19–21} thus

suggesting that strategies for AF prevention in DM patients should focus on the control of DM-associated comorbidities (especially the weight and blood pressure control).¹⁹

Indeed, in the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicon Modified Release Controlled Evaluation) study, DM patients with AF (7.6%) had significantly greater risks for all-cause death, cardiovascular death, major cerebrovascular events, and heart failure compared with DM patients without AF. Blood pressure lowering yielded similar relative risk reduction in all-cause and cardiovascular mortality but owing to their higher risk of these events, the absolute benefits from blood pressure control appeared much greater in AF patients.²² In the VALUE (Valsartan Antihypertensive Long-term Use Evaluation) trial, hypertensive patients with new-onset DM had higher rates of new-onset AF compared with non-DM patients and were at higher risk of heart failure.²³ Hence, AF in DM patients should be viewed as a marker of adverse outcome, which should prompt aggressive management of all concomitant risk factors (Figure 3).²⁴ Importantly, intensive glucose lowering (target HbA1c <6.0%) has been associated with similar incident AF rates as a less stringent approach (HbA1c <8.0%), but with increased risk of death and other cardiovascular events.¹⁷

Since asymptomatic (silent) AF is not uncommon, especially in patients with DM,²⁵ at least opportunistic screening for AF with pulse palpation should be performed in DM patients, as also recommended





Figure 3 General principles of management of cardiac arrhythmias in patients with diabetes mellitus. AADs, antiarrhythmic drugs; ACEi, angiotensin-converting enzyme inhibitor; AFL, atrial flutter; AHI, apnoea-hypopnea index; ARB, angiotensin receptor blocker; AVNRT, atrioventricular nodal re-entrant tachycardia; AVRT, atrioventricular re-entrant tachycardia; BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; CPAP, continuous positive airway pressure; CRT, cardiac resynchronization therapy; CV, cardiovascular; DM, diabetes mellitus; ECG, electrocardiogram; HT, hypertension; ICD, implantable cardioverter-defibrillator; LA, left atrium; LV, left ventricle; MRI, magnetic resonance imaging; NOACs, non-vitamin K antagonist oral anticoagulants; OAC, oral anticoagulant therapy; PM, pacemaker; SE, systemic embolism; VKA, vitamin K antagonist; VPBs, ventricular premature beats; VT ns, ventricular tachycardia non-sustained.

III. TREATMENT OF VENTRICULAR ARRHYTHMIAS IN DM



III. TREATMENT OF SUPRAVENTRICULAR ARRHYTHMIAS IN DM




Figure 3 Continued.

Table 2 Randomized controlled trials of intensive vs. standard glycaemic control in adult patients with diabetes mellitus

Study, year	Cohort size	Drug	Intensive glucose control	Follow-up	Study outcomes (intensive vs. standard glucose control)	Significant hypoglycaemia
ADVANCE ⁷² , 2008	11 140 DM type 2	Gliclazide	HbA1c $\leq 6.5\%$	Median 5 years	<p>Microvascular events: 9.4% vs. 10.9%; HR 0.86 (0.77–0.97), $P = 0.01$</p> <p>Macrovascular events: 10.0% vs. 10.6%; HR 0.94 (0.84–1.06), $P = 0.32$</p> <p>Cardiovascular death: 4.5% vs. 5.2%; HR 0.88 (0.74–1.04), $P = 0.12$</p> <p>All-cause death: 8.9% vs. 9.6%; HR 0.93 (0.83–1.06), $P = 0.28$</p>	2.7% vs. 1.5%; HR 1.86 (1.42–2.40), $P < 0.001$
ACCORD ⁵⁴ , 2008 ACCORD ⁵³ , 2011	10 251 DM Type 2, known CV dis- ease or CV risk factors	Various; The intensive regimen stopped early due to increased mortality	HbA1c $< 6.0\%$	Mean 3.5 years	<p>All-cause death: 1.41% vs. 1.14%; HR 1.22 (1.01–1.46), $P = 0.04$</p> <p>Cardiovascular death: 2.6% vs. 1.8%; HR 1.35 (1.04–1.76), $P = 0.02$</p> <p>Fatal arrhythmia: 0.1% vs. 0.2%</p> <p>Primary outcome (composite of non-fatal MI, stroke or CV death): 6.9% vs. 7.2%; HR 0.90 (0.78–1.04), $P = 0.16$</p> <p>*At 5-year follow-up, the rates of non-fatal MI were lower [1.18% vs. 1.42%, HR 0.82 (0.70–0.96), $P = 0.01$] but the rates of CV death (0.72% vs. 0.57%, HR 1.29 (1.04–1.60), $P = 0.02$) and all-cause death [1.53% vs. 1.27%, HR 1.19 (1.03–1.38), $P = 0.02$] were higher with intensive glucose control.</p> <p>Fatal arrhythmia: 0.1% vs. 0.4%</p>	3.1% vs. 1.0%, $P < 0.001$
VADT ⁷³ , 2009	1791 military vet- erans; DM Type 2, 40% with pre- vious CV event	Various; Open-label study	An absolute reduction for 1.5% points in HbA1c com- pared with standard glu- cose control	Median 5.6 years	<p>6-year event free rates, stand- ard vs. intensive control:</p> <p>Cardiovascular death: 0.96% vs. 0.95%; HR 1.32 (0.81–2.14), $P = 0.26$</p> <p>All-cause death: 0.88% vs. 0.87%; HR 1.07 (0.81–1.42), $P = 0.62$</p> <p>Time to first occurrence of a CV event: HR 0.88 (0.74–1.05), $P = 0.14$</p>	21.2% vs. 9.9%, $P < 0.001$

Continued

Table 2 Continued

Study, year	Cohort size	Drug	Intensive glucose control	Follow-up	Study outcomes (intensive vs. standard glucose control)	Significant hypoglycaemia
NICE-SUGAR ⁷⁴ , 2009 NICE-SUGAR ⁵¹ , 2012	6104 critically ill patients	Insulin	Blood glucose 4.5–6.0 mmol/l	90 days	90-Day all-cause mortality: 27.5% vs. 24.9%; OR 1.14 (1.02–1.28), $P = 0.02$ *Both moderate and severe hypoglycaemia are associated with increased risk of death: 28.5% vs. 23.5%, HR 1.41 (1.21–1.62), $P < 0.001$ (moderate hypoglycaemia); 35.4% vs. 23.5%; HR 2.10 (1.59–2.77), $P < 0.001$ (severe hypoglycaemia)	6.8% vs. 0.5%, OR 14.7 (9.0–25.9), $P < 0.001$ Moderate hypoglycaemia $n = 2714$ (45.0%); Severe hypoglycaemia $n = 223$ (3.7%)
ORIGIN ⁵² , 2013	12 537 DM Type 2 with additional CV risk factors	Insulin glargine	Normal glycaemia	Median 6.2 years	Severe hypoglycaemia vs. others: Composite of CV death/MI or stroke: HR 1.58 (1.24–2.02), $P < 0.001$ All-cause mortality: HR 1.74 (1.39–2.19), $P < 0.001$ CV mortality: HR 1.71 (1.27–2.30), $P < 0.001$ Arrhythmic death: HR 1.77 (1.17–2.67), $P = 0.07$	Annual rates of severe hypoglycaemia 0.9% vs. 0.3%

ACCORD, The Action to Control Cardiovascular Risk in Diabetes trial; ADVANCE, The Action in Diabetes and Vascular Disease: Preterax and Diamicon Modified Release Controlled Evaluation trial; CV, cardiovascular; DM, diabetes mellitus; HR, hazard ratio; MI, myocardial infarction; NICE-SUGAR, The Normoglycaemia in Intensive Care Evaluation—Survival Using Glucose Algorithm Regulation trial; OR, odds ratio; ORIGIN, Outcomes Reduction with an Initial Glargine Intervention; VADT, Veterans Affairs Diabetes Trial.

for all individuals aged ≥ 65 years.²⁶ High-risk DM patients would likely benefit from an active screening for AF, but more data are needed to define optimal AF screening strategy(ies) in DM patients.²⁷ Before treatment initiation, the presence of AF should be documented using a 12-lead electrocardiogram (ECG).^{26,28} In DM patients with established AF, ventricular rate control is recommended to decrease symptoms and prevent AF-related complications. In patients with persistent symptoms, despite adequate rate control, or in those with left ventricular dysfunction attributable to poorly controlled high ventricular rate, or as per patient's preference, rhythm control strategy could be attempted²⁹ including catheter ablation^{30–32} or cardioversion. Of note, DM has been associated with increased AF recurrence post successful cardioversion of persistent AF.³³ For AF-related stroke risk management see *Stroke risk assessment and prevention in arrhythmias associated with endocrine disorders*.

Ventricular arrhythmias and sudden cardiac death

Compared with the general population, DM patients have an increased risk of both SCD^{13,32–35} and non-SCD.³⁶ In a meta-analysis of 14 studies involving 346 356 participants and 5647 SCD cases, the risk of SCD was

two-fold higher in patients with DM compared with non-DM patients [adjusted hazard ratio (HR) 2.25, 95% CI 1.7–2.97].²⁹ However, DM patients were also shown to be at nearly three-fold greater risk of non-SCD than non-DM patients (adjusted HR 2.90, 95% CI 1.89–4.46).³⁶ Observational studies reported marked QTc prolongation,³⁷ atypical microvolt T-wave alternans patterns,³⁸ altered heart rate variability,^{39–43} or heart rate turbulence^{44–46} in DM patients, but none of these tests have been routinely used to stratify the risk for ventricular arrhythmias or SCD in clinical practice.⁴⁷ Both hyper- and hypoglycaemia have been independently associated with increased risk of ventricular arrhythmias.⁴⁸ Insulin-induced hypoglycaemia has been associated with nocturnal death (so-called 'dead-in-bed syndrome') in DM type 1,^{49,50} and arrhythmic deaths were reported in several DM type 2 trials^{51–54} (Table 2).

There is no DM-specific protocol of screening for SCD⁴⁷ but, as shown in Figure 3, all patients diagnosed with DM should undergo regular screening for cardiovascular risk factors or structural heart disease, and glycaemic targets should be set individually. Patients with DM and symptoms suggestive of cardiac arrhythmias (e.g. palpitations, pre-syncope, or syncope) should undergo further detailed diagnostic assessment as shown in Figure 3.

Hypoglycaemia-associated arrhythmias are difficult to document, but observational studies using continuous glucose monitoring (CGM) and Holter monitoring in small DM type 2 cohorts ($n = 25$) showed that hypoglycaemic episodes were common, often asymptomatic and associated with various arrhythmias.^{55,56} Compared with daytime hypoglycaemia, nocturnal episodes were more common and associated with greater risk for bradycardia or atrial ectopy, whilst ventricular arrhythmias were equally common.⁵⁵ In contrast to animal studies,⁵⁷ in a recent retrospective analysis of the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial, the use of beta-blockers in DM patients was associated with increased risk of severe hypoglycaemia and cardiovascular events,⁵⁸ but more evidence is needed to inform optimal use of beta-blockers in DM patients without established CAD.⁵⁹ Otherwise, the use of antiarrhythmic drugs should follow the general principles and precautions related to pharmacological treatment of cardiac arrhythmias.^{26,47}

In high-risk patients with established cardiovascular disease and/or long-standing sub-optimally controlled DM type 2, a less stringent glycaemic control (i.e. a target HbA1c of $\leq 8\%$) is recommended,⁶⁰ since intensive glycaemic control has been associated with increased risk of severe hypoglycaemic episodes counterbalanced by significant reduction only in microvascular but not macrovascular complications (e.g. MI, stroke, and mortality). The addition of empagliflozin⁶¹ or liraglutide⁶² to standard care should be considered in order to reduce

cardiovascular and all-cause mortality or hospitalization for heart failure.⁶³ In addition, the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial data suggested that liraglutide may have a renal protective effect.^{62,64} Although cardiac arrhythmias were not specifically investigated in either LEADER or EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients)⁶⁰ trial, an antiarrhythmic effect of these drugs (perhaps mediated via glucagon release stimulation) has been hypothesized to contribute to the reduced risk for cardiovascular death.^{61,62}

The CANVAS Program data showed that the use of another sodium-glucose co-transporter 2 (SGLT2) inhibitor, canagliflozin, was associated with significantly lower risk of cardiovascular events and a renal protective effect compared with placebo in patients with DM type 2 and an elevated risk of cardiovascular disease.⁶⁵ The incidence of cardiovascular events with dapagliflozin is currently investigated in the DECLARE-TIMI 58 trial,⁶⁶ and a meta-analysis of 21 trials with this drug⁶⁷ suggested the potential for a beneficial cardiovascular effect consistent with the multifactorial benefits on cardiovascular risk factors associated with other SGLT2 inhibitors.^{68,69} Concerning the cardiovascular effects of the SGLT1 inhibitors other than liraglutide (i.e. exenatide and lixisenatide), there was no significant difference in the rates of cardiovascular events with these agents compared with placebo in the respective trial.^{70,71}









Consensus statements	Consensus statement instruction	Level of evidence	References
Diagnostic assessment of patients with DM type 1 and type 2 requires aggressive screening for and a detailed characterization of underlying cardiovascular risk factors, atherosclerotic cardiovascular disease and DM-related factors (i.e. glucose regulation, diabetic neuropathy, and cardiomyopathy), all of which may increase the risk of cardiac arrhythmias and SCD in DM patients	'Should do this'		⁶
Glycaemic targets in patients with DM and cardiac arrhythmias should be defined individually, taking into account patient age, individual risk profile, life expectancy and patient values and preferences	'Should do this'		⁶⁰
Severe hypoglycaemia should be avoided in DM patients at risk of cardiac arrhythmias, owing to increased risk of malignant, potentially lethal ventricular arrhythmias and all-cause death	'Should do this'		⁶⁰
Intensive glucose control with target HbA1c of $<7.0\%$ (or even $<6.0\%$) should not be attempted in elderly and/or high-risk DM patients, owing to increased risk of severe hypoglycaemia and neutral (or negative effect) on all-cause mortality	'Do not do this'		⁶⁰
Intense management of cardiovascular risk factors (e.g. obesity, dyslipidaemia, hypertension, obstructive sleep apnoea, etc.) in DM patients reduces the risk of cardiac arrhythmias (e.g. AF) by preventing (or slowing) the development of atherosclerotic cardiovascular disease and arrhythmogenic substrate	'Should do this'		²⁶
Incident AF in DM patients should be viewed as a marker of increased risk of adverse cardiovascular events and mortality. Intensive glucose control does not reduce the risk of AF, but aggressive management of cardiovascular risk factors may delay or prevent AF	'Should do this'		²⁶
Screening for silent AF by pulse palpation (with ECG confirmation) should be performed in all DM patients at each regular visit.	'Should do this'		^{26,27}
The use of (non-selective) beta-blockers in DM patients without established CAD may be weighed against the risk of severe hypoglycaemia	'May do this'		^{58,59}

Table 3 Definitions of thyroid dysfunction⁶

	TSH levels (mIU/L)	Free thyroxine (pmol/L)	Total thyroxine (mmol/L)
Thyroid function			
Euthyroidism	0.2–5.0	9–22	60–140
Overt hypothyroidism	>5.0	<9	<60
Subclinical hypothyroidism	>5.0	9–22	60–140
Overt hyperthyroidism	<0.2	>22	>140
Subclinical hyperthyroidism	<0.2	9–22	60–140
TSH level dependent thyroid dysfunction			
Euthyroidism	0.4–5.0	9–22	60–140
High-normal euthyroidism	0.2–0.4	9–22	60–140
Subclinical hyperthyroidism (reduced TSH)	0.1–0.2	9–22	60–140
Subclinical hyperthyroidism (suppressed TSH)	<0.1	9–22	60–140

TSH, thyroid stimulating hormone.

Thyroid dysfunction

Thyroid dysfunction is associated with atrial and ventricular tachyarrhythmias, as well as bradyarrhythmias. Hyperthyroidism is accompanied by increased automaticity and triggered activity in the atria and pulmonary veins (PVs), while in hypothyroidism effective refractory periods of the atria, atrioventricular (AV) node, bypass tracts and His-Purkinje system are prolonged.^{75–77} Genetic mechanisms involving ion channels, and autoimmune mechanisms involving muscarinic and beta-adrenoreceptors, that are also linked to long-QT syndrome, may contribute to ventricular and atrial arrhythmias in thyroid dysfunction.^{78,79} Tachy- and bradyarrhythmia occurrence is different in hyperthyroidism and hypothyroidism, and the evidence on treatment is limited (Table 3–5).

Hyperthyroidism

Hyperthyroidism, overt or subclinical [i.e. reduced serum thyroid stimulating hormone (TSH) concentration but free thyroxine levels within reference ranges] (Table 3) is associated with increased risk of AF^{80–90}; before and after establishment of the diagnosis, it is associated with increased risk of cardiovascular disease development.⁹¹ Hypothyroidism, either overt or subclinical has been shown by several studies confer no AF risk,^{80,89,90} though lack of association is not well-established.^{92–97}

Atrial fibrillation

Antithyroid treatment and attainment of euthyroid state should be the first line in management of AF in the setting of hyperthyroidism, as in most cases AF reverses spontaneously to sinus rhythm once euthyroid state is achieved, usually after 13–15 weeks of therapy.^{98–101} Treatment using antithyroid agents, radioiodine therapy, or thyroidectomy is accompanied by conversion to sinus rhythm in 75–100% of cases, but predictors of persistent arrhythmia are increased age, longer pre-treatment duration of AF and hyperthyroidism.^{99,100} For rate control of AF and as an adjunct to antithyroid therapy, non-selective beta-blockers like propranolol may be used, as they exert not only antisymphatic effects slowing heart rate but also reduce metabolic rate and affect triiodothyronine levels; in case of low-output heart

failure they should be used cautiously or other short-acting beta-blockers without intrinsic sympathomimetic activity should be considered.^{102–104} It is reasonable to recommend cardioversion in patients with persistent AF after establishment of euthyroid state, and in case of recurrent AF when the patient is euthyroid, ablation should be considered.^{101,105–110} In patients with persistent AF related to hyperthyroidism, cardioversion results in restoration of sinus rhythm in 88–92.4%; in patients without accompanying structural heart disease, 86% and 67% of them were arrhythmia-free at 3 years and 6.7 years of follow-up, respectively.^{105,106}

Hyperthyroidism-related AF usually has a lower recurrence rate than non-hyperthyroidism-related AF. In one study, where only electrical cardioversion was used, the risk of AF recurrence was 36% lower in hyperthyroidism than in non-hyperthyroidism AF ($P = 0.004$) and the only predictor of AF recurrence was the longer duration of arrhythmia ($P < 0.01$).¹⁰⁷ Few studies have reported outcomes of AF ablation,^{108–110} with no difference in long-term (4 years) recurrence rate between hyperthyroidism and non-hyperthyroidism-related AF after PV isolation,¹⁰⁹ while in another study recurrence was two-fold higher in hyperthyroid than in non-hyperthyroid patients after single procedure of PV isolation or substrate ablation, while after multiple procedures there was no difference.¹¹⁰

Hyperthyroidism does not independently confer higher risk for stroke/systemic embolic events as compared to non-hyperthyroid patients,^{111–113} and annual risk of stroke in hyperthyroid patients with AF is lower than in non-hyperthyroid patients.¹¹⁴ Warfarin reduced the risk of ischaemic stroke in non-self-limiting AF patients with hyperthyroidism and $\text{CHA}_2\text{DS}_2\text{VASc} \geq 1$.¹¹⁴

Ventricular arrhythmias

While ventricular arrhythmias are rare in hyperthyroid patients; one of the earliest Holter monitoring studies did not demonstrate reduction of ventricular ectopy with antithyroid therapy.¹¹⁵ However, QT prolongation is described in Graves disease with thyrotoxicosis.¹¹⁶ Few cases of isolated VF without structural heart disease and electrolyte imbalance in hyperthyroidism have been reported,¹¹⁷ among them coronary vasospasm was confirmed in two, one case was due

Table 4 Evidence summary for arrhythmias associated with thyroid dysfunction

Study	Design	Subjects	Follow-up	Thyroid dysfunction	Arrhythmia	Risk (95%CI)
Selmer <i>et al.</i> ⁸⁰	Cohort	586 460	5.5 years	Euthyroidism	AF	Reference
				Overt hyperthyroidism	2.9%	IRR 1.42 (1.22–1.63)
				Subclinical hyperthyroidism	4.6%	IRR 1.31 (1.19–1.44)
				Overt hypothyroidism	2.5%	IRR 0.67 (0.5–0.9)
				Subclinical hypothyroidism		IRR 0.87 (0.7–0.97)
				TSH levels		IRR 1.16 (0.99–1.36)
				Reduced TSH		IRR 1.41 (1.35–1.89)
				Suppressed TSH		IRR 1.12 (1.03–1.21)
Colett <i>et al.</i> ⁸⁶ Thyroid studies collaborators	Meta-analysis	52 674	8.8 years	Subclinical hyperthyroidism	AF	HR 1.68 (1.16–2.43)
				Reduced TSH		HR 1.63 (1.1–2.4)
				Suppressed TSH		HR 2.54 (1.08–5.99)
Kim <i>et al.</i> ⁹⁰ Framingham Heart study	Cohort	5055	10 years	TSH 0.45–4.5 µU/L–5.4	AF	Reference
				TSH 4.5–10.0 µU/L–7.0		HR 1.23 (0.77–1.97)
				TSH 10.0–19.9 µU/L–4.0		HR 0.57 (0.21–1.54)
Brandt <i>et al.</i> ⁹¹	Observational cohort	2631 pts with hyperthyroidism 10 524 controls 67 years 81% female	6 years	Hyperthyroidism/Controls	CVD + arrhythmia 26% 19%, $P < 0.001$	HR 1.34 (1.15–1.56)
Kobayashi <i>et al.</i> ¹¹⁷	Summary of cases	10 pts w/o CVD and hypokalaemia	–	Hyperthyroidism	VF isolated	
				1 patient with amiodarone- induced thyroid dysfunction		
				1 early repolarization		
				2 cases coronary vasospasm		

AF, atrial fibrillation; CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio; IRR, incidence rate ratio; pts, patients; TSH, thyroid stimulating hormone; VF, ventricular fibrillation.

to amiodarone-induced toxicity and one case was accompanied by early repolarization. All cases were treated with antithyroid therapy, prednisolone, beta-blockers and in some cases an implantable cardioverter-defibrillator (ICD) was used.¹¹⁷ It should be noted also that antithyroid therapy might worsen early repolarization and arrhythmia.¹¹⁷

Bradyarrhythmias

Bradyarrhythmias, AV block and sick sinus syndrome (SSS), are rare entities in hyperthyroid patients;^{118,119} one study reported that only 3% of AV block cases with pacemaker implantation were due to primary hyperthyroidism.¹¹⁸

Hypothyroidism

Hypothyroidism is accompanied by ventricular arrhythmias and conduction disturbances. One case-control study of 152 hypothyroid and 152 euthyroid patients, revealed higher prevalence of VT ($P=0.04$) and ventricular arrhythmias ($P=0.007$) in hypothyroid patients¹²⁰ and Torsades de Pointes with prolongation of QT interval and bradycardia may develop in hypothyroidism.^{121–127} It is advised to consider hypothyroidism in differential diagnosis of polymorphic

VT. The VT/VF, accompanying hypothyroidism requires correction with thyroid hormones, DC shock in urgent cases, correction of electrolyte balance, and bradycardia if QT prolongation and Torsades de Pointes arrhythmia. If arrhythmia is sustained or recurs, the implantation of ICD could be considered.¹²⁸

Rarely, in patients with implanted pacemakers and ICDs, overt or subclinical hypothyroidism due to functional changes in tissue might increase pacing threshold or create exit block in atrial and ventricular pacing leads that usually are reversible by correction of thyroid status.^{129–132}

Conduction abnormalities in the setting of hypothyroidism are represented by fascicular blocks (14.2%), 1st degree AV block (11.9%),¹³³ advanced AV block, and sinus node dysfunction.^{118,134,135} There are also case reports on advanced AV block of 2nd and 3rd degree reversed by thyroid replacement therapy and temporary pacemaker implantation in overt and subclinical hypothyroidism.^{136–140} Several reports describe underlying hypothyroidism playing a role in development of lithium-induced sinus node dysfunction, reversed after treatment of hypothyroidism.^{134,135} Treatment of subclinical hypothyroidism should follow the recent update on thyroid disease management.⁸⁸

Table 5 Evidence summary for treatment of arrhythmias associated with thyroid dysfunction









Study	Design	Subjects	Treatment	Follow-up	Arrhythmia after treatment	Comment
Effect of antithyroid treatment on arrhythmia						
Nakazawa et al. ⁹⁸	Prospective	163 pts hyperthyroidism and AF 46.7 years	Antithyroid therapy - 9% RIT+ antithyroid therapy -87% Thyroidectomy 3%	34 months	101 pts with spontaneous AF conversion to sinus rhythm upon attainment of euthyroidism 63 pts persistent AF	Intervals between return to euthyroidism and spontaneous AF conversion to sinus rhythm <1 week 43% 1–3 weeks 75.2% 4–6 weeks – 87.1% 7–9 weeks – 93.1% 10–12 weeks – 97% 13–15 weeks 100% >16 weeks -100%
Zhou et al. ⁹⁹	Prospective	94 pts hyperthyroidism 41.2 years PAF: 38 pts Pers. AF: 45 pts	Radioiodine therapy	1.6 years	PAF: 0% Pers. AF: 60%	Predictors of pers. AF Age >55 years RR 2.76, 1.16–8.79, $P < 0.01$ Duration of hyperthyroidism RR 3.08, 1.22–11.41, $P < 0.01$ Duration of pre-treatment AF RR 2.96, 1.31–7.68, $P < 0.01$
Tsymbaluk et al. ¹⁰⁰	Prospective	61 pts hyperthyroidism due to Graves disease	Antithyroid therapy	Euthyroid state	AF: 25% PAC: 7%	AF rate before and after antithyroid therapy 72% to 25%, $P < 0.001$ PAC: 71–7%, $P < 0.001$
Gauthier et al. ¹⁰¹	Retrospective	40 pts with hyperthyroidism due to GD and 40 euthyroidism multinodular goiter	Thyroidectomy	Before and after operation	AF: 0 (sinus rhythm in 100%) Sinus tachycardia -68.8%	–
Treatment of persistent AF after antithyroid treatment						
Nakazawa et al. ¹⁰⁵	Prospective	33 pts with persistent AF	Cardioversion after Antithyroid treatment for hyperthyroidism	35 months	AF—12% SR—88%	AF free survival—86%
Nakazawa et al. ¹⁰⁶	Retrospective	106 pts with persistent AF w/o SHD 47.6 years	Cardioversion after Antithyroid treatment for 3 months for hyperthyroidism	6.7 years	AF—7.6% SR—92.4%	Predictor of AF recurrence Duration of AF HR 1.6 (1.14–2.26), $P = 0.005$ Late follow-up: SR—67%
Siu et al. ¹⁰⁷	Prospective case-controlled	116 pts 58 hyperthyroidism-related persistent AF 58 non-hyperthyroidism AF	ECV after Antithyroid treatment for 3 months for hyperthyroidism	24 months	–	AF recurrence Hyperthyroidism—59% Non-hyperthyroidism—83% Risk of AF recurrence hyperthyroidism vs non-hyperthyroidism HR 0.64 (0.39–0.97), $P = 0.004$ Predictor of AF recurrence Longer duration of AF HR 1.01 (1.0–1.01), $P < 0.01$

Continued

Table 5 Continued

Study	Design	Subjects	Treatment	Follow-up	Arrhythmia after treatment	Comment
Machino et al. ¹⁰⁹	Prospective	337 pts Persistent AF with history of hyperthyroidism 4.7% (16) w/o hyperthyroidism 95.3% (321)	First AF ablation (PVI) after 3 months of antithyroid therapy for hyperthyroidism	4 years	—	AF recurrence hyperthyroidism—44% no hyperthyroidism—43% Predictors of AF recurrence hyperthyroidism HR 0.87 (0.40–1.88), P = 0.73
Wongcharoen et al. ¹¹⁰	Prospective	717 pts	First AF ablation (PVI and substrate modification 12%) >3 month treatment of hyperthyroidism before ablation	—	AF	Predictor of AF recurrence after single procedure: History of hyperthyroidism OR 2.07 (1.27–3.38) AF recurrence did not differ after multiple procedures
Stroke risk in hyperthyroidism-related AF Chan et al. ¹¹¹	Observational cohort AntiT and risk of ischemic stroke in hyperthyroidism-related AF	Of 9727 pts with non-valvular AF 642 (6.6%) pts with hyperthyroidism 136 pts—warfarin 243— aspirin 263—no AntiT 71.9 years 67.8% female	Hyperthyroidism vs non-hyperthyroidism	2 years	Non-valvular AF	Warfarin Reduced risk of stroke by 67% HR 0.33 (0.12–0.91) Annual risk of stroke by CHA ₂ DS ₂ Vas score hyperthyroidism-AF vs non-hyperthyroid-AF 0—0 vs. 2.56 1—2–3.17 vs. 7.02 ≥3—8.11 vs. 10.54 Ischaemic stroke 7.8% Warfarin reduced risk of stroke in non-self-limiting AF CHA ₂ DS ₂ Vasc≥1— P = 0.04 But not in self-limiting AF
Bruere et al. ¹¹⁴	Prospective	8962 pts with AF	141 hyperthyroidism history 510 hypothyroidism history 8271 euthyroidism	929 days	AF	Stroke SE hyperthyroidism HR 0.85 (0.41–1.76) hypothyroidism HR 0.98 (0.73–1.34) Bleeding hypothyroidism HR 1.3 (1.02–1.79)
Friberg et al. ¹¹²	Swedish Atrial Fibrillation Cohort Study	90 490 patients No anticoagulation at baseline	Thyroid disease 84 Thyrotoxicosis 553 pts	1.5 years	AF	Ischemic stroke Thyroid disease HR 0.95 0.70–1.19 Thyrotoxicosis HR 0.92 (0.85–1.05) Stroke/TIA/systemic emboli Thyroid disease HR 1.00 (0.92–1.09) Thyrotoxicosis HR 1.03 (0.83–1.28)
Petersen et al. ¹¹³	Retrospective	610 patients	Hyperthyroidism	Stroke Within 1 year after 1 year	AF - 91 (14.9%)	Stroke, n 1st year after 1st year Sinus rhythm 87 AF 57

AF, atrial fibrillation; AIT, amiodarone-induced toxicity; AntiT, antithrombotic therapy; CA, catheter ablation; CI, confidence interval; CVD, cardiovascular disease; ECV, electrical cardioversion; HR, hazard ratio; IRR, incidence rate ratio; OR, odds ratio; pts, patients; RIT, radioiodine therapy; RR, relative risk; TIA, transient ischaemic attack; TSH, thyroid stimulating hormone; VT, ventricular tachycardia; VF, ventricular fibrillation.

Recommendations on management of tachy- and bradyarrhythmias associated with thyroid dysfunction	Consensus statement instruction	Level of evidence	References
Correction of thyroid dysfunction with restoration of euthyroid state is one of the primary goals in the treatment of tachy- and bradyarrhythmias associated with hyperthyroidism or hypothyroidism	'Should do this'		98–101
Correction of subclinical forms of thyroid dysfunction associated with tachy- and bradyarrhythmias may be required	'May do this'		88,91
Referral to endocrinologists should be considered for selection of appropriate thyroid function therapy (thyrosuppressive therapy, radioiodine therapy, and thyroidectomy)	'Should do this'		99–101
Hyperthyroidism-related AF that persists after euthyroid condition has been achieved (>3 months of thyrosuppressive therapy) should be managed using cardioversion or ablation for rhythm control. Antithrombotic therapy should be applied as for non-hyperthyroid-AF	'Should do this'		26,105–114
Rare cases of VT/VF in the setting of hyperthyroidism should be managed using antiarrhythmics (caution with amiodarone—see below), DC shock in cases of hemodynamic compromise and therapy with an ICD if indicated. Associated conditions—coronary vasospasm, early repolarisation, amiodarone toxicity should be taken in account	'Should do this'		95,117,128
Severe bradyarrhythmias accompanying hyperthyroidism and hypothyroidism might require use of temporary pacemaker; in persistent cases, after restoration of euthyroid condition, bradyarrhythmias should be managed according to the current guidelines	'Should do this'		118,136–141
VT/VF accompanying hypothyroidism associated with long QT interval should be managed with correction of bradycardia and electrolyte imbalance; avoid antiarrhythmic drugs that prolong the QT interval. In acute cases, DC shock may be necessary. If VT/VF persists, therapy with an ICD should be considered	'Should do this'		95,121–128
Monitoring and correction of thyroid dysfunction may be considered if lead dysfunction/change in atrial or ventricular pacing thresholds appear in patients with implanted pacemakers and ICDs	'May do this'		129–132

Amiodarone-induced thyroid dysfunction

About 10.3–14.7% of patients taking amiodarone for treatment of ventricular and atrial tachyarrhythmias, and 16.7% of patients receiving amiodarone for control of inappropriate ICD shocks develop amiodarone-induced thyroid dysfunction (Table 6).

Amiodarone-induced thyroid dysfunction manifests as amiodarone-induced hyperthyroidism with two distinctive types: type 1, which develops in presence of underlying thyroid disease with excessive hormone production in response to iodide load associated with amiodarone leading to true hyperthyroidism and type 2, destructive thyroiditis that develops due to direct toxic effects of iodine associated with amiodarone. Differential diagnosis of two types of hyperthyroidism usually is done using ultrasonography, thyroid I¹³¹ uptake and thyroid [99m Tc] 2-methoxy-isobutyl-isonitrile (MIBI) scintigraphy.^{142,143} Management of amiodarone-induced thyroid dysfunction depends on above-mentioned types of dysfunction, with hormone replacement therapy for amiodarone-induced hypothyroidism, antithyroid medications for amiodarone-induced hyperthyroidism type 1 and steroids for amiodarone-induced hyperthyroidism type 2 (thyroiditis), and use of antithyroid medications and steroids in cases of coexistence of hyperthyroidism and thyroiditis.^{142,144} Generally, accepted approaches in prevention and early detection of

amiodarone-induced thyroid dysfunction are baseline assessment of thyroid function (thyroxine and TSH levels) before initiation of amiodarone treatment and periodic monitoring of thyroid function (within 3 months after initiation and every 3–6 months thereafter),^{145–147} though latest studies demonstrated conflicting results, with no association of amiodarone-induced thyroid dysfunction occurrence and periodic testing of thyroid hormones, it should be mentioned also that 49.5% of patients had detectable abnormalities in thyroid function tests prior to development of amiodarone-induced dysfunction.¹⁴⁸ Thyroid stimulating hormone receptor autoantibody test and ultrasonography may be used for differential diagnosis of type I and type II thyroid dysfunction.¹⁴⁷

Overt thyroid dysfunction occurs in 3.6–3.7% of patients receiving amiodarone for prevention of SCD and 10.3–14.7% of patients receiving amiodarone for treatment of ventricular arrhythmias and AF^{149–153} and 16.7% of patients taking amiodarone for control of inappropriate ICD shocks.¹⁵⁴ Meta-analyses of RCTs on secondary prevention of SCD and adverse effects of amiodarone in patients treated for ventricular arrhythmias reported 4.2–5.7-fold increased risk of thyroid dysfunction and 1.78–2.18 times higher risk for development of bradyarrhythmias^{149,150} when compared with placebo groups; about 1/3rd–1/

Table 6 Summary of evidence for amiodarone-induced thyroid dysfunction

Study	Design	Population	Follow-up	Thyroid dysfunction/ toxicity, arrhythmia	Predictors of toxicityOR/ RR/HR (95%CI)
Piccini et al. ¹⁴⁹	Met-analysis 15 RCTs of amio vs. placebo effi- cacy in preven- tion of SCD, safety	8522 pts 4260 amio arm 4262 placebo arm	12–45.5 months	Thyroid 3.6% vs. 0.4% Pulmonary 2.9% vs. 1.5% Hepatic 1.85% vs. 0.7% Bradyarrhythmias 2.8% vs. 1.5%	OR 5.68 (2.94–10.98), $P < 0.0001$ OR 1.97 (1.27–3.04), $P = 0.002$ OR 2.1 (1.15–3.82), $P = 0.015$ OR 1.78 (1.16–2.72), $P = 0.008$ Amio discontinuation rate 31.6%
Vorperian et al. ¹⁵⁰	Meta-analysis 4 RCTs amio vs. placebo Adverse effects	738 pts amio arm 727 pts placebo arm low dose amio 100–400 mg maintenance dose	12–45 months	TD 3.7% vs. 0.4% Bradycardia 3.3% vs. 1.4% Discontinuation rate 22.9% vs. 15.4% Skin: 2.3% vs. 0.7% Eye: 1.5% vs. 0.1%	OR 4.23 (2.04–8.74), $P = 0.001$ OR 2.18 (1.11–4.27), $P = 0.024$ OR 1.60 (1.23–2.09), $P < 0.0001$ OR 2.48 (1.05–6.17), $P = 0.05$ OR 3.42 (1.22–3.64), $P = 0.02$
Bathcer et al. ¹⁵¹ Substudy of SAFE-T	RCT substudy	612 pts with persistent AF Amio vs Sotalol+ placebo	1–4.5 years	Hypothyroidism Subcl.: 25.8% vs 6.6%, $P < 0.0001$, Overt: 5.0% vs. 0.3%, $P < 0.001$ Hyperthyroidism Subcl.: 1 case amio, Overt: 5.3% vs. 2.4%, $P = 0.07$	—
Ross et al. ¹⁵²	Cohort study	163 patients Amio for: SVT: 102 pts, VT: 55 pts, Prevention: 3 pts, Uncertain: 1 pt	679 days	Hypothyroidism Subclinical: 7.4% Overt: 8% Hyperthyroidism Subcl.: 0.6% Transient hyperthyroidism: 0.6% Overt: 6.7%	—
Kinoshita et al. ¹⁵⁵	Retrospective cohort study For overt thyroid dysfunctions Indication for amio VA: 66.7–80% AA: 20–33.3%	317 pts Euthyroid: 256 Subcl. hypothy- roid: 52 Subcl. hyperthy- roid: 9 58.5 years, 73.5% males	5 years	Overt hyperthyroidism 9.5% Overt hypothyroidism 18.9%	Predictors of hyperthyroidism : DCM OR 3.3 (1.26–8.9) Sarcoidosis OR 6.47 (1.6–25.77) Predictors of hypothyroidism: Free T4—OR 0.13 (0.03–0.68) TSH—OR 1.47 (1.26–1.74)
Ahmed et al. ¹⁵³	Prospective	303 pts Amio for: AF-260 pts, VA: 43 pts 63 years, 66% males	3.3 years	Hyperthyroidism 8% Hypothyroidism 6%	Hyperthyroidism Age <62 years HR 2.4 (1.0–5.7), $P < 0.05$ Hypothyroidism: TSH >1.4 mU/L HR 5.1 (1.1–22.4), $P = 0.03$ LVEF <45% HR 3.8 (1.1–13.3), $P = 0.04$ DM-HR 3.3 (1.1–10.3), $P = 0.04$
Lee et al. ¹⁵⁴	Retrospective Amio vs sotalol and beta-	55 pts with ICD Amio: 24 pts Sotalol: 17 pts	4 years	Hypothyroidism 16.7% Time to development 16.3(23) months	

Continued

Table 6 Continued

Study	Design	Population	Follow-up	Thyroid dysfunction/ toxicity, arrhythmia	Predictors of toxicityOR/ RR/HR (95%CI)
Shiga et al. ¹⁵⁶	blockers for inappropriate shock reduction in ICD pts	Beta-blockers: 19		Treatment Dose reduction in amio hypo- thyroidism group and dis- continuation in pulmonary toxicity group (16.7%) pts	
	Prospective Recurrence of VT/ VF during amio- darone induced toxicity as com- pared to euthy- roid state Holter monitoring and plasma amio	232 pts amio therapy	2 years	Hypothyroidism 10.8% No change in arrhythmia recurrence and plasma amio Hyperthyroidism 12.5% VT/VF recurrence: euthyroid 1 vs. hyperthyroid 9 pts, $P < 0.01$; VPC three-fold increase, $P < 0.05$, No change in plasma amio Treatment Hypothyroidism: 12-L-thyro- xine, no discontinuation of amio hyperthyroidism: 6 methimi- zole, 2 prednisolone, 3 amio discontinuation, 18—grad- ual improvement	
Czarnywojtek et al. ¹⁶¹	Cohort RIT for pts on amio and TD Amio indication: SVT, VT, ICD inappropriate shocks, AF	297 cases amio A 78: euthyroid- ism on amio B118: hyperthyroidism History amio C 79: hyperthy- roidism amio D 22: hypothyroidism	12 months	Recurrence of hypothyroid- ism after RIT: A: 53.8%, B: 33.9% , C: 34.1% Recurrence of hyperthyroid- ism after RIT: A: 7.7%, B: 12.5% , C: 11.4% ABC: reinstated amio after 3–6 weeks of RIT D: permanent hypothyroid- ism—thyroxine replacement therapy	
Diederichsen et al. ¹⁶⁴	RCT double-blind placebo- controlled Amio vs place bo for 8 weeks after catheter ablation of AF Endpoint: TD	212 patients after catheter ablation of AF without history of thy- roid dysfunction Amio group: 8 weeks amio Placebo group	6 months	Thyroid dysfunction Amio discontinuation Amio group—3 Placebo—1 Amio group significantly higher TSH, fT4 and T4 and lower fT3 and T3 at 1 and 3 months as compared to placebo TD after 1 month of amio treatment	

AA, atrial tachyarrhythmias; AF, atrial fibrillation; Amio, amiodarone; CI, confidence interval; CVD, cardiovascular disease; DM, diabetes mellitus; ECV, electrical cardioversion; HR, hazard ratio; ICD, implantable-cardioverter defibrillator; IRR, incidence rate ratio; LVEF, left ventricular ejection fraction; OR, odds ratio; pts, patients; RCT, randomized controlled trial; RIT, radioiodine therapy; RR, relative risk; subcl., subclinical; SVT, supraventricular tachycardia; TD, thyroid dysfunction; TSH, thyroid stimulating hormone; VA, ventricular arrhythmia; VPC, ventricular premature complexes; VT, ventricular tachycardia; VF, ventricular fibrillation.








4th of patients discontinued amiodarone treatment. Amiodarone-induced thyroid dysfunction includes overt and subclinical hypothyroidism and hyperthyroidism,^{151,152} although changes in thyroid hormone levels in euthyroid patients on amiodarone treatment are common without clinical manifestations of amiodarone-induced thyroid dysfunction.¹⁴² In the SAFE-T (Sotalol-Amiodarone Fibrillation Efficacy) trial, overt hypothyroidism developed in 5.0%, subclinical hypothyroidism in 25.8% and overt hyperthyroidism in 5.3% and its subclinical form only in one patient in amiodarone arm that were significantly higher than in control arm receiving sotalol or placebo for treatment of persistent AF ($P < 0.05$ for all).¹⁵¹ In another cohort study of patients receiving amiodarone for ventricular and atrial tachyarrhythmias, subclinical and overt hypothyroidism developed in 7.4% and 8% of patients, respectively; and subclinical and overt hyperthyroidism in 0.6% and 6.7%, respectively, after 943 days of treatment.¹⁵² Though the evidence on predictors of amiodarone-induced thyroid dysfunction is limited, two studies^{153,155} addressed the issue of identifying patients at risk of thyroid dysfunction: in one study, patients with low thyroxine and high TSH levels were at risk of hypothyroidism development, while patients with dilated cardiomyopathy and sarcoidosis had 3.3 and 6.47-fold increased risk of hyperthyroidism development,¹⁵⁵ it should be noted that patients with subclinical thyroid dysfunction at baseline were also included

in the study. In another prospective study of patients with AF and ventricular arrhythmias receiving amiodarone, 8% of patients developed hyperthyroidism and 6% of patients—hypothyroidism during 3.3 years of follow-up, and the only predictor for development of hyperthyroidism was age < 62 years, while hypothyroidism risk was associated with TSH levels > 1.4 mU/L, low ejection fraction and DM.¹⁵³

In summary, amiodarone-induced overt thyroid dysfunction occurs in approximately 10.3–14.7% of patients with arrhythmias receiving amiodarone and should be suspected if symptoms of toxicity develop, including tachy- and bradyarrhythmias, other organs lesions and change in thyroid tests (Table 3).

Of note, amiodarone-induced thyroid dysfunction depends neither on dose,¹⁵⁰ nor on plasma concentration of amiodarone,¹⁵⁶ but tachy- and bradyarrhythmias may occur. Holter monitoring study in patients with VT/VF receiving amiodarone treatment demonstrated statistically significant increase in recurrence of VT and ventricular premature complexes in hyperthyroid state when compared with baseline euthyroid state,¹⁵⁶ and in rare cases of thyroid storm VT/VF may develop.¹²⁸ Withdrawal of amiodarone and switching to other antiarrhythmic drugs can be effective in treatment of VT/VF episodes due to amiodarone-induced thyroid dysfunction.¹⁵⁷

Bradyarrhythmias usually occur in hypothyroidism, AV block tends to develop in presence of pre-existing conduction abnormality.⁷⁷

Recommendations on management of amiodarone-induced thyroid dysfunction	Consensus statement instruction	Level of evidence	References
Before prescribing amiodarone therapy for long-term use it is recommended to weigh risk/benefit of its toxicity and strongly consider catheter ablation to cure or modify the substrate for arrhythmias instead	'Should do this'		145,149–151
It is recommended to carry out baseline thyroid tests (thyroxine and TSH) before initiation of amiodarone treatment); thyroid-directed autoantibodies and ultrasonography should be considered for differential diagnosis of type I and type II amiodarone-induced hyperthyroidism.	'Should do this'		116,117,119,120,142, 143,145–147,163
It is advised to monitor thyroid function tests and ECG for amiodarone-induced thyroid dysfunction screening	'Should do this'		145,147,148
If hyperthyroidism occurs during treatment with amiodarone, its discontinuation MANDATORY. The eventual decision to initiate or continue amiodarone once the euthyroid state is achieved for preventing life-threatening ventricular tachyarrhythmias should be carefully evaluated in each individual case in terms of expected risk and benefits.	'Do not do this'		142,143,145,154,161,165
Hypothyroidism should be treated with thyroid replacement agents, and amiodarone therapy may be continued if necessary.	'Should do this'		145,156,165
In case of VT/VF withdraw amiodarone and treat using antiarrhythmics and DC shock, if hemodynamic compromise.	'Should do this'		128,156
The use of amiodarone in elderly patients increases the risk of bradyarrhythmias, such as advanced AV block or SSS, requiring a permanent pacemaker.	'Should do this'		141,160

Amiodarone-induced thyroid dysfunction may manifest as SSS, constituting 22% of all causes of SSS.^{158–160} In some circumstances, correction of thyroid dysfunction in patients with AF and bradycardia developed on amiodarone treatment unmasks underlying tachycardia-bradycardia syndrome.¹⁵⁹

Withdrawal of amiodarone therapy should be strongly considered in cases of hyperthyroidism; proper management of VT/VF, AV block and SSS is required. In a study of amiodarone-induced thyroid dysfunction in patients receiving amiodarone for prevention of inappropriate shocks, dose reduction of amiodarone was adequate to reduce signs of amiodarone-induced thyroid dysfunction.¹⁵⁴ Latest studies on use of antithyroid therapy in patients requiring long-term amiodarone treatment (ventricular/atrial arrhythmias or inappropriate shock reduction in ICD patients) demonstrated that application of antithyroid radioiodine therapy might be an option to reinstitute amiodarone treatment¹⁶¹; radioiodine ablation of thyroid is also an option in amiodarone-induced thyroid dysfunction with resistant tachyarrhythmias.¹⁶²

It is recommended also to weigh the risk of amiodarone-induced thyroid dysfunction before considering the long-term treatment or prefer treatment like catheter ablation. Monitoring of thyroid function every 6 months and electrocardiogram follow-up in patients on amiodarone therapy should be considered.^{145,148,163}





Pheochromocytoma

The prevalence of pheochromocytoma (PCC) discovered during life is 0.15–0.4%; however, many cases remain undiscovered as the prevalence noted in autopsy studies is higher.¹⁶⁶ The clinical picture ranges from totally asymptomatic patients to life-threatening complications including MI, severe heart failure,

Tako-tsubo cardiomyopathy, and arrhythmias. Typically, additional release of catecholamines by PCC is accompanied by paroxysmal headache, sweating, hypertension, and palpitations. Therefore, recurrent arrhythmias in such clinical context should raise the suspicion of PCC. Palpitations are present in one-half to 70% of patients.¹⁶⁷

Arrhythmia mechanisms include beta-adrenergic stimulation of the heart, alpha1-adrenergic stimulation (especially during myocardial ischemia and reperfusion),¹⁶⁸ desensitization of adrenergic cardiovascular receptors due to prolonged adrenergic stimulation and reflex increase in vagal tone. Most often sinus tachycardia is encountered. However, a large spectrum of arrhythmias could be part or the first clinical manifestation of PCC, before typical signs are present. It includes mostly supraventricular arrhythmias and AF but also malignant and bidirectional VT.¹⁶⁹ Some PCC patients manifest with reflex bradycardia, asystole, AV dissociation, Wolf-Parkinson-White syndrome or SSS.¹⁷⁰ Patients with PCC may present with repolarization abnormalities consisting of marked QT prolongation and deep, wide inverted T wave¹⁷¹ with subsequent risk for Torsades des Pointes.

Esmolol, a beta1-adrenergic cardioselective blocker with rapid onset of action can be used to control fast rate due to AF or atrial flutter (0.5 mg/kg iv followed by continuous infusion of 0.1–0.3 mg/kg/min).¹⁷⁰ Associated alpha-blockade (i.e. phenoxybenzamine 10 mg once to 10–30 mg twice or α1 blockade with prazosin—starting with 1 mg and increasing to 1 or 2 mg two or three times daily) may be used to prevent the incidence of hypertensive crisis during beta blockade. There is no specific treatment for other arrhythmias and VT could respond to lidocaine.¹⁷²

Recommendations on management of PCC	Consensus statement instruction	Level of evidence	References
Pheochromocytoma should be considered as possible diagnosis in patients with paroxysmal headache, hypertension, palpitations, and recurrent arrhythmia	'Should do this'		167
Esmolol should be used to control rapid rate in AF and flutter. Associated alpha blockade is mandatory to prevent hypertensive crisis	'Should do this'		170
Lidocaine may be used to treat sustained VT	'May do this'		169,172,173
As PCC can prolong QTc interval, antiarrhythmic drugs prolonging the QTc should be used with caution and only after QTc monitoring	'Should do this'		171

Growth hormone dysfunction

Acromegaly

Acromegaly is a rare and debilitating disease with a prevalence of 40 per million, characterized by increased growth hormone (GH) and insulin-like growth factor-1 (IGF-1). Early clinical trials have demonstrated a two-fold increase in overall mortality in patients with acromegaly when compared with general population, with cardiovascular causes accounting for 40–60% of all deaths.^{174–176} Acromegalic cardiomyopathy is characterized by biventricular hypertrophy progressing to diastolic and systolic dysfunction culminating in heart failure in 10% of patients.^{177–179} Recent cohorts, with patients treated early in the disease course, suggest lower rates of cardiovascular involvement.^{180,181} Classically, mononuclear cell infiltration,¹⁸² apoptosis,¹⁸³ myofibrillary abnormalities,¹⁸⁴ interstitial fibrosis, oedema, and cardiomyocyte hypertrophy are characteristic of acromegalic cardiomyopathy and may represent the histological substrate for arrhythmias.^{184,185}

Cardiac arrhythmias in acromegaly

There is paucity of data on the prevalence and severity of cardiac arrhythmias in acromegaly.^{186–188} Supraventricular arrhythmias are uncommon in patients with acromegaly with one study reporting supraventricular arrhythmias in 6/27 patients while two other show absence of any increase.^{188–190} Asymptomatic sinus node disease has also been described in a small proportion of patients in another study.¹⁹¹ However, complex ventricular ectopy is common, occurring in 40–48% of acromegalic patients^{188,189,192} and increasing with exercise.¹⁸⁸ The ventricular ectopy increased with duration of

acromegaly and severity of ectopy correlated with left ventricular mass but not GH levels.¹⁸⁸ Sustained VT and sudden death has been reported in patients with acromegaly with severe cardiomyopathy.^{193–195} Late potentials are common in acromegalic cardiomyopathy and correlate with frequency of ventricular ectopy.^{181,192} Similarly, greater QT dispersion (dQT) and prolonged QTc interval are seen in active acromegaly and may predispose to ventricular tachyarrhythmia.^{196,197}

Impact of acromegaly specific treatment on cardiac arrhythmias

There is lack of longitudinal studies evaluating the impact of treatment of acromegaly on associated cardiac arrhythmia. However, there is indirect evidence to suggest that control of acromegaly in early stages may decrease cardiac remodelling,¹⁸⁰ development of late potentials,¹⁸¹ ventricular arrhythmia,^{198–200} and cardiac mortality.²⁰¹

Growth hormone deficiency

Growth hormone deficiency is diagnosed in 0.1% of the population in general clinical practice and is characterized by the short stature, frontal bossing, central obesity, and high-pitched voice.²⁰² Growth hormone deficiency usually manifests early in childhood, while in adults it may be accompanied by increased sensitivity to insulin in patients with diabetes and manifests with fine wrinkling around eyes and mouth. Deficiency of GH, adrenocorticotrophic hormone and gonadotropin, and hypothyroidism are common in hypopituitarism.²⁰³ Though rarely, tachy- and bradyarrhythmias may accompany GH deficiency.^{204,205} In one prospective study of pituitary hormone levels in patients who underwent




Figure 4 Effect of aldosterone on the cardiovascular system.²¹⁵ Catechol, catecholamine; LVH, left ventricular hypertrophy.

cardiopulmonary resuscitation due to VT/VF, GH deficiency was present in 27.5% of them,²⁰⁴ with (GH)-IGF-1 being significantly lower in a group of patients with GH deficiency when compared with group of patients with normal GH values. There are also reports on increased cardiovascular morbidity in children with GH deficiency treated with GH, due to cardiomegaly.²⁰⁵ A complete AV block was described in a child with GH deficiency during therapy with hGH, treated successfully by pacemaker implantation.²⁰⁵

Thus, cardiac evaluation and monitoring is reasonable in patients with GH deficiency and during its therapy.

Diseases of adrenal cortex

Hyperaldosteronism

Primary hyperaldosteronism (PH) also known as Conn's disease, is an endocrine disorder caused by an adrenal adenoma (uni- or bilat-

eral). It causes hypertension, hypokalaemia, metabolic alkalosis, and renin suppression.^{206–208} Long-standing PH has been associated with myocardial injury, leading to heart failure and either atrial or ventricular arrhythmias.^{209–214} Figure 4 summarizes the effect of aldosterone on the cardiovascular system.²¹⁵

Management of PH associated arrhythmias focuses on controlling metabolic and electrolyte disturbances.²¹⁶ Deleterious cardiovascular effects can be controlled by either performing aldosterone receptor blockade or adrenalectomy.²¹⁷ Tables 7 and 8 summarize PH related arrhythmias.

Specific data on indications for device implantation in PH patients is very limited and general guideline recommendations apply for this population. The main treatment approach for this condition is either surgical resection of the adrenal adenoma or pharmacological therapy targeting adrenal hyperplasia.^{207–210}

Table 7 Electrocardiographic disorders associated with PH

Prolonged QT-interval ²¹⁸
Atrial fibrillation ^{219,220}
Atrial flutter ²²¹
Ventricular tachycardia ²²²
Polymorphic ventricular tachycardia ^{223,224}
Ventricular fibrillation ^{225–227}

PH, primary hyperaldosteronism

Adrenal insufficiency

Primary adrenal insufficiency (PAI), also known as Addison's disease, it is characterized by corticosteroid and mineralocorticoid deficiency.^{230,231} Patients with PAI typically present with hyponatraemia, hyperkalaemia, hypoglycaemia, and hyperpigmentation. Cardiac manifestations include hypotension, syncope, arrhythmias, and cardiomyopathy. Acute exacerbations are called Addisonian crises.²³² Table 9 summarizes the most common cardiac abnormalities and ECG findings, which are usually reversible with definitive treatment of the underlying cause.^{231,233}

Table 8 Description of the most important studies on PH

Study	Type of study	Number of patients (n)	AF (%)	VT (%)	Sustained arrhythmias (%)
Milliez et al. ²¹²	Case control	124	7.3	NA	NA
Catena et al. ²²⁸	Prospective cohort	54	NA	NA	15
Born et al. ²²²	Retrospective cohort	640	7.1	NA	NA
Mulatero et al. ²²¹	Case control	270	NA	NA	7.8
Savard et al. ²²⁹	Case control	459	3.9	NA	NA

AF, atrial fibrillation; NA, data not available; PH: primary hyperaldosteronism; VT, ventricular tachycardia.

Recommendations

Consensus statement instruction

Level of evidence

References

Primary hyperaldosteronism patients with atrial or ventricular arrhythmias should receive treatment for stabilization of their electrolyte and metabolic disturbances

'Should do this'



216,217

In PH patients with persistent rhythm abnormalities or myocardial damage, pacemakers or high voltage devices may be used according to life expectancy and response to optimal medical therapy

'May do this'






218,225,226

Table 9 Cardiac abnormalities associated with PAI

Idiopathic dilated cardiomyopathy ²³⁴
Tako-tsubo cardiomyopathy ²³⁵
ECG:
Low voltage ²³⁶
Sinus bradycardia ²³⁷
Prolonged PR-interval ²³⁷
Prolonged QT-interval ²³⁸
T-wave inversion ²³⁹
Brugada like-pattern ²⁴⁰
Polymorphic ventricular tachycardia ²⁴¹
Ventricular fibrillation ²³⁷

ECG, electrocardiogram; PAI, primary adrenal insufficiency.

Recommendations	Consensus statement instruction	Level of evidence	References
Patients with PAI and ECG changes should be treated for electrolyte and metabolic disturbances	'Should do this'		²³⁰
Patients with PAI in the setting of dilated cardiomyopathy and/or heart failure who receive optimal medical therapy should be started on hydrocortisone and fludrocortisone. Fludrocortisone should be used with caution because; excessive fluid retention may lead to, or worsen heart failure symptoms	'Should do this'		^{231,232}
Patients with PAI and persistent rhythm abnormalities or myocardial damage may be candidates for pacemakers or high voltage device therapy based on life expectancy and response to optimal medical therapy	'May do this'		²³³

Parathyroid disease

Hypoparathyroidism and hyperparathyroidism are rare hormone disorders characterized by abnormally low or high levels of the parathyroid hormone (PTH). Physiologically, PTH plays a critical role in the

regulation of calcium homeostasis through several mechanisms. The consequence of PTH deficiency is hypocalcaemia, which can cause QT interval prolongation and arrhythmias. In clinical practice, however, torsades de pointes or other life-threatening tachyarrhythmias are infrequent in patients with hypoparathyroidism, despite extreme QT prolongation.²⁴² In the literature, there is only one case report of a patient with hypoparathyroidism who suffered VF probably due to heart failure and severe hypocalcaemia.²⁴³ Severe hypocalcaemia requires treatment as soon as possible with intravenous calcium. Long-term treatment of hypoparathyroidism includes calcium and Vitamin D supplementation for the stable control of plasma calcium levels.²⁴³


The main biochemical feature of primary hyperparathyroidism is hypercalcaemia. Hypercalcaemia may induce arrhythmias through both early and delayed ventricular after depolarization. Previous studies have shown that primary hyperparathyroidism and hypercalcaemia are directly related to electrocardiographic abnormalities, such as high-amplitude QRS complex, short ST segment and QT interval, and T wave extension.²⁴⁴ A variety of arrhythmias, such as sinus arrest, supraVT and AF has been documented in patients with primary hyperparathyroidism.²⁴⁵ Furthermore, ventricular arrhythmias in association with hyperparathyroidism have been reported, including ventricular bigeminy, VT, and VF.^{246–248} Although patients with hyperparathyroidism have an increased risk of death, it is not known if arrhythmias play any role in increased cardiovascular mortality. The most effective method for the treatment of primary hyperparathyroidism is parathyroidectomy. However, the role of surgery regarding the effect on cardiac arrhythmia risk is controversial. Some studies did not report a reduced incidence of mortality in hyperparathyroidism after parathyroidectomy, while the other showed that parathyroidectomy reduced the occurrence of ventricular arrhythmias and restored the QTc adaptation during exercise test.^{249–251} A series of case reports indicate that in rare cases ventricular storm induced by hyperparathyroidism may be controlled only after parathyroid surgery.^{247,248,252,253}

Sex hormones-related differences in the risk of arrhythmias

It is well recognized that men and women differ with respect to the risk of developing arrhythmias.^{3,254–256} The mechanisms involved in these differences have not been fully elucidated, but may be related to the electrophysiological effects of sex hormones. In experimental studies,^{257,258} 17 β -oestradiol has protective effects on ischemia-induced arrhythmias and reduces L-type Ca²⁺ current (ICaL). Nevertheless, estrogens may partially suppress the delayed rectifier K⁺ current (IKr), thus enhancing drug-induced APD and QTc prolongation. Progesterone increases slow activating delayed rectifier K⁺ current (IKs) and modulates ICaL, therefore promoting APD shortening. Testosterone also regulates both IKs and ICaL in a dose-dependent manner and results in shortening of APD.^{257,258}

Women have higher resting heart rate, shorter PR and QRS intervals, and longer QTc intervals, whereas men more frequently exhibit early repolarization.^{3,254–256} Notably, repolarization differences between men and women do not occur in prepubertal children.²⁵⁹ Repolarization is also affected by the ovarian cycle: since repolarizing currents are increased by progesterone and decreased by oestrogen,

QTc is longer in the follicular phase when compared with the luteal phase.^{255,258} The longer repolarization renders women more susceptible to drug-induced Torsades de Pointes.²⁶⁰ Therefore, QT prolonging drugs should be used carefully in females, particularly in those with other abnormalities, such as electrolyte imbalance. Accordingly, progesterone may attenuate drug-induced QTc lengthening.²⁶¹ Also, women have greater arrhythmic risk than men in congenital LQTS, especially after puberty.²⁶² Further emphasizing the role of hormonal modulation in arrhythmia development, in congenital LQTS, the risk of life-threatening events is reduced during pregnancy but increased in the postpartum period.²⁶³ On the other hand, Brugada syndrome and AF predominate in men.^{254–256} It is well known that women have a higher incidence of AV nodal re-entry tachycardia and inappropriate sinus tachycardia.²⁶⁴ Exacerbation of supraventricular tachycardias may occur during pregnancy, likely due to hormonal and autonomic tone changes.²⁶⁵

Recommendations	Consensus statement instruction	Level of evidence	References
QT prolonging drugs (www.crediblemeds.org) should always be used carefully in both women and men. However, due to an increased risk of drug-induced Torsades de Pointes, this recommendation should be further emphasized for women, particularly in the presence of electrolyte imbalance	'Should do this'		^{260,261}

Stroke risk assessment and prevention in arrhythmias associated with endocrine disorders

As described in previous sections, the presence of various endocrine disorders can be associated with AF, which is the arrhythmia most commonly associated with increased risk of stroke and thromboembolism. Older small studies¹¹³ have suggested an association between thyroid disease and an increased risk of stroke in AF. In the largest analysis from the Swedish AF cohort study,¹¹² a nationwide cohort of 182 678 subjects with AF, thyroid disease (HR 0.95, 95% CI 0.85–1.05) or

thyrotoxicosis (HR 0.92, 95% CI 0.70–1.19) were not independent predictors of ischaemic stroke in multivariate analysis. Similarly, either thyroid disease or thyrotoxicosis were not independent predictors of major bleeding or intracranial haemorrhage. Similar observations were noted in the Loire Valley AF project, where history of hyperthyroidism was not an independent risk factor for stroke/systemic embolism, whereas hypothyroidism was associated with a higher risk of bleeding events.¹¹⁴ Thus, AF patients with thyroid disease are associated with stroke or thromboembolism only in association with other established stroke risk factors, the most common of them are included within the CHA₂DS₂-VASc score.²⁶⁶ Similar for stroke or thromboembolism, risk assessment should be used to identify patients at risk for bleeding, and to address the potentially reversible bleeding risk factors, as advocated by validated practical bleeding risk scores such as the HAS-BLED score.²⁶⁷




Diabetes mellitus is well established as a clinical stroke risk factor in AF and is incorporated into the CHA₂DS₂-VASc score.^{266,268} Duration of diabetes may accentuate stroke risk, but not bleeding risk.²⁶⁹ Indeed, duration of diabetes may be a more important predictor of ischaemic stroke than glycaemic control in such patients.²⁷⁰

Whilst diabetic complications such as diabetic retinopathy are associated with higher risks, such evidence of ‘diabetic target organ damage’ does not independently add to stroke or bleeding risk prediction.²⁷¹

With regard to prevention of stroke, the most important measure is oral anticoagulation (OAC) whether given as a Vitamin K antagonist (VKA, e.g. warfarin) with good quality anticoagulation control (with “time in therapeutic range” or TTR >70%) or a non-VKA oral anticoagulant (NOAC, e.g. dabigatran, rivaroxaban, apixaban, or edoxaban). The NOACs are the preferred option in most patients starting anicoagulation, but given the heterogeneity of AF patients and the availability of different OAC options, we should fit the drug to the patient profile. In general, NOACs appear relatively more effective and safer than VKA in reducing stroke/systemic embolism and major bleeding irrespective of patient comorbidities.²⁷²

In summary, AF stroke risk stratification even with concomitant endocrine disorders should use the established CHA₂DS₂-VASc score²⁶⁶ to initially identify ‘low risk’ patients (CHA₂DS₂-VASc 0 in males or 1 in females) who do not need any antithrombotic therapy, followed by prevention of stroke (i.e. OAC) in patients with >1 risk factor.

As OAC is being initiated, a clinical bleeding risk score such as HAS-BLED score (see above) should be used to identify patients at risk for bleeding, and importantly, to address the potentially reversible bleeding risk factors (that should be considered in all patients, irrespective of HAS-BLED score value). The next step is to consider choice of OAC, and the SAMe-TT₂R₂ score²⁷³ can be used to aid decision making between a VKA with likelihood of a good TTR (score 0–2) or those less likely to achieve it, thus requiring more regular INR checks, or as a better option, use of a NOAC.²⁷⁴ This simple three-step pathway has been advocated to help streamline decision making for stroke prevention in AF.²⁷⁴

Recommendations	Consensus statement instruction	Level of evidence	References
Irrespective of underlying endocrine abnormalities (which should be concurrently managed), the CHA ₂ DS ₂ -VASc score should be used to initially identify 'low risk' patients (CHA ₂ DS ₂ -VASc 0 in males or 1 in females) who do not need any antithrombotic therapy, followed by prevention of stroke (ie, OAC) in patients with >1 risk factor	'Should do this'		266,274
As OAC is being initiated, a clinical bleeding risk score such as HAS-BLED score should be used to identify patients at risk for bleeding (HAS-BLED ≥ 3)	'Should do this'		266,267,274
Importantly, potentially reversible bleeding risk factors should be considered in all patients, irrespective of HAS-BLED score value			
The SAME-TT ₂ R ₂ score may be used to aid decision making between a VKA with likelihood of a good TTR (score 0–2) or those less likely to do so, thus requiring more regular INR checks, or as a better option, use of a NOAC	'May do this'		273,274

Catheter ablation of arrhythmias associated with endocrine disorders

Catheter ablation for atrial or ventricular arrhythmia is optimally performed in as much as possible stable electrolytic and metabolic conditions, in order to avoid transient arrhythmias. Arrhythmias associated with endocrine disorders would theoretically need no ablation since they are supposed to spontaneously disappear once return to steady state is obtained. They may also alter the analysis of targets to be ablated and interpretation of results for complex procedures. However, ablation sometimes needs to be performed in patients with acute or subacute endocrine disorders. This may apply to patients with severe ventricular tachyarrhythmia and electrical storm, or atrial tachyarrhythmia with haemodynamic compromise not efficiently treated with other methods.

Diabetes

A meta-analysis of 15 studies and 1464 patients indicated that catheter ablation of AF in patients with diabetes had similar safety and efficacy than that in the general population, especially when performed in younger patients with satisfactory glycaemic control.²⁹ Catheter ablation of AF reduces the amount of patients requiring antiarrhythmic drugs, an additional benefit in a population commonly exposed to adverse effects of AF pharmacological treatments.

Thyroid disorders

FT4 levels may influence the success rate of AF ablation procedures, even within the normal range.^{275,276} It has been found that right atrial non-PVs triggers were more prevalent in AF patients treated with thyroid hormone replacement. After elimination of non-PV triggers, there was still a worse arrhythmia-free survival in these patients.²⁷⁷ Patients with hyperthyroid history have a higher number of PV ectopic beats and higher prevalence of non-PV ectopic foci compared with euthyroid patients, which may result in a higher AF recurrence rate after ablation procedure.¹¹⁰ Catheter ablation for

paroxysmal AF in patients with amiodarone-induced hyperthyroidism is usually safe and effective albeit with higher rate of early AF recurrences up to 3 months after PV isolation relative to controls, but not beyond 12 months.²⁷⁸ Pulmonary vein isolation alone may have a lower efficacy for preventing recurrence in paroxysmal AF in these patients with amiodarone-induced hyperthyroidism, which may need repeat ablations.²⁷⁹

Device-based therapy of arrhythmias in patients with endocrine disorders

Diabetes and long-term treatment with chronic corticosteroids (frequently prescribed in endocrine disorders) are important factors associated with an increased risk of infections of cardiac electrical implanted devices (CIEDs), as shown in Table 8.^{280–284} Pacemaker- and ICD-related infections represent one of the most difficult complications that may occur in a patient implanted with a CIED. There is increasing concern on the important clinical and economic consequences of the rise in the incidence of CIEDs-related infections that have occurred in the last 10 years.^{280–284} The incidence of pacemaker- and ICD-related infections has been reported to range between 0.1% and 19.9%, for pacemakers, and between 0.8% and 9.5% for ICDs, including biventricular devices, in observational studies with different follow-up durations.^{280–284} Cardiac electrical implanted devices infections usually appear as infections limited to the device pocket, often with fistulas and skin erosion, but lead endocarditis may be detected in around one out of 10 cases, with an incidence of 0.06–0.6%.^{280–284} The outcome of CIED infections is characterized by serious events including a high risk of death, so preventive measures are mandatory, on the basis of appropriate identification of risk factors (Table 10).

In patients with an ICD or a device for cardiac resynchronization therapy (CRT) implanted, diabetes influences outcome, similarly to other comorbidities included in the Charlson comorbidity score.²⁸⁵ The comorbidities that are represented in the Charlson comorbidity

Table 10 Risk of CIED infection according to a series of risk factors, as reported in literature^{280–284}

	Odds ratio for the risk of CIED infection
Patient factors	
Male gender	1.5
Younger age	1.4–4.5
Diabetes	2.3–3.5
Chronic kidney disease	4.6–6.3
Haemodialysis	8.6
Treatment with anticoagulants	2.6–3.4
Chronic corticosteroid use	9.1
History of malignancy	4.0
Underlying heart disease	3.1
High Charlson co-morbidity index	2.7–3.0
Fever, systemic infection	5.8
Device or procedure-related factors	
Prior CIED infection	11.3
≥3 implanted leads	4.0–5.4
Device replacement, device upgrades or implant revision	1.7–3.1
Early reinterventions	2.7–15
Temporary pacing prior to implantation	2.5
Post-operative haematoma at pocket site	4.0–6.7
Physician experience	2.5

CIED, cardiac electrical implanted device.

score are independent predictors of death, all-cause, and cardiovascular hospitalizations, as well as of days spent alive and out of hospital.²⁸⁶ In a report from the United States on more than 18 000 patients with a cardiac resynchronization therapy-defibrillator (CRT-D) device implanted, patients with diabetes had a higher mortality than those without diabetes, both at 1 and 3 years,²⁸⁷ in agreement with a meta-analysis based on five studies on cardiac resynchronization in heart failure.^{288,289} However, these findings have to be analysed in combination with the evidence derived from randomized studies that CRT is equally effective in reducing mortality vs. control in diabetic as compared to non-diabetic patients.^{288,290}

The effectiveness of ICDs for primary prevention of SCD in patients with diabetes has raised great interest since diabetes, as well as other comorbidities, may be also associated with a high risk of non-arrhythmic cardiac and non-cardiac death. This complex topic has been studied through subanalysis of randomized trials, systematic reviews, and meta-analysis.²⁹¹ The subanalysis of diabetic patients in randomized clinical trials provides reassurance, since the beneficial effect of ICD on survival is confirmed both in patients with and without diabetes.^{291–293} The frequent association between diabetes and chronic kidney disease (CKD) is of great relevance, since CKD *per se* may condition the outcome and the benefits after implant of a ICD or a CRT device.²⁹⁴

In patients implanted with a defibrillator the occurrence of AF due to hyperthyroidism may induce inappropriate shocks and requires proper management.²⁵⁸ Hyperthyroidism, either due to primary

thyroid disease or secondary to amiodarone treatment, should be excluded in any case of new-onset of atrial tachyarrhythmias.^{295,296}

Hypothyroidism has been associated with poor outcomes in patients with heart failure and therefore it is of interest to assess the outcome of patients with previous diagnosis of hypothyroidism after CRT device implantation. In a case series of heart failure patients implanted with CRT a history of hypothyroidism was present in 16.4% and was an independent predictor of poor outcome (cardiac death heart failure hospitalization or need for heart transplant).^{297,298}

Current research gaps, ongoing trials and future directions

Most of the information present in the literature is based on registries and the communication of some exceptional cases. Mostly, there are no data on the specific effect of hormones on heart rate disturbances, and their effects are estimated based on structural remodelling and associated comorbidities (i.e. changes in blood pressure, obesity, sleep disorders, or increased catecholamine levels). Importantly, there is scarce evidence of the real incidence of arrhythmias in endocrine diseases. Indeed, the lack of clinical trials with specific attention to the effect on arrhythmias is general. Specific randomized trials are needed beyond drug safety, where only the effect on heart rhythm disturbances is very marginal.

Different trials are searching for the biological effect of antidiabetic drugs on heart rhythm. For example, it has led to study the effects of intravenous exenatide on cardiac repolarisation,²⁹⁹ exploring changes to QTc interval changes. In the same line, Addhope 2 trial³⁰⁰ studies the heart rate variability modifications with liraglutide in patients with ischaemic heart disease and newly diagnosed DM type 2.

An interesting field is the diagnosis of AF in patients treated for hyperthyroidism. In this setting, there is a thumb-ECG ambulant screening for AF in this type of patients,³⁰¹ though in clinical setting other monitoring methods can be used. Whereas TABLAS study explores the influence of subclinical hyperthyroidism on the results of AF ablation.³⁰²

Regarding PCC, the PRESCRIPT trial compares phenoxybenzamine vs. doxazosin, and assesses the differences in high blood pressure and tachycardia episodes.³⁰³ There is also an ongoing study in acromegaly patients; it is exploring the effects of repeated subcutaneous injection with BIM23B065—a somatostatin 2 receptor agonist—in acromegalic patients³⁰⁴ on blood pressure, heart rate, and QT interval.

Cardiac arrhythmias in endocrine disorders are frequent and modify the natural history of the disease. These facts invite cardiologists to participate in future research and trials to explore pathophysiologic pathways, diagnosis and therapeutic approach in endocrine disorders.

Supplementary material

Supplementary material is available at *Europace* online.

Acknowledgements

The authors thank EHRA Scientific Documents Committee: Gregory Y.H. Lip, Laurent Fauchier, David Arnar, Carina Blomstrom-Lundqvist, Zbigniew Kalarus, Gulmira Kudaiberdieva, Georges H.

Mairesse, Tatjana Potpara, Irina Savelieva, Jesper Hastrup Svendsen, Vassil B. Traykov.

Conflict of interest: none declared.

References

- Lengyel S, Vira L, Kova PP, Kristo A, Pacher P, Kocsis E. Role of slow delayed rectifier K-current in QT prolongation in the alloxan-induced diabetic rabbit heart. *Acta Physiol* 2008;**192**:359–62.
- Ballou LM, Lin RZ, Cohen IS. Control of cardiac repolarization by phosphoinositide 3-kinase signaling to ion channels. *Circ Res* 2015;**116**:127–37.
- Boriani G, Lorenzetti S, Cerbai E, Oretto G, Bronzetti G, Malavasi VL et al. The effects of gender on electrical therapies for the heart: physiology, epidemiology, and access to therapies: a report from the XII Congress of the Italian Association on Arrhythmology and Cardiac Stimulation (AIAC). *Europace* 2017;**19**:1418.
- Gilles AM. Atrial fibrillation and ventricular arrhythmias: sex differences in electrophysiology, epidemiology, clinical presentation, and clinical outcome. *Circulation* 2017;**135**:593–608.
- Lang F, Shumilina E. Regulation of ion channels by the serum and glucocorticoid inducible kinase SGK1. *FASEB J* 2013;**27**:3–12.
- American Diabetes A. 9. Cardiovascular disease and risk management. *Diabetes Care* 2017;**40**(Suppl 1): S75–87.
- Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. *Circulation* 2000;**102**:1014–9.
- Scirica BM, Bhatt DL, Braunwald E, Raz I, Cavender MA, Im K et al. Prognostic implications of biomarker assessments in patients with type 2 diabetes at high cardiovascular risk: a secondary analysis of a randomized clinical trial. *JAMA Cardiol* 2016;**1**:989.
- Tse G, Lai ET, Tse V, Yeo JM. Molecular and electrophysiological mechanisms underlying cardiac arrhythmogenesis in diabetes mellitus. *J Diabetes Res* 2016;**2016**:1.
- Koektuerk B, Aksoy M, Horlitz M, Bozdog-Turan I, Turan RG. Role of diabetes in heart rhythm disorders. *World J Diabetes* 2016;**7**:45–9.
- Fox CS, Coady S, Sorlie PD, Levy D, Meigs JB, D'Agostino RB Sr et al. Trends in cardiovascular complications of diabetes. *JAMA* 2004;**292**:2495–9.
- Cho E, Rimm EB, Stampfer MJ, Willett WC, Hu FB. The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. *J Am Coll Cardiol* 2002;**40**:954–60.
- Balkau B, Jouven X, Ducimetiere P, Eschwege E. Diabetes as a risk factor for sudden death. *Lancet* 1999;**354**:1968–9.
- Chamberlain AM, Agarwal SK, Folsom AR, Soliman EZ, Chambless LE, Crow R et al. A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk in Communities [ARIC] study). *Am J Cardiol* 2011;**107**:85–91.
- Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. *Am J Cardiol* 1998;**82**:2N–9N.
- Dublin S, Glazer NL, Smith NL, Psaty BM, Lumley T, Wiggins KL et al. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. *J Gen Intern Med* 2010;**25**:853–8.
- Fatemi O, Yuriditsky E, Tsoufis C, Tsachris D, Morgan T, Basile J et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). *Am J Cardiol* 2014;**114**:1217–22.
- Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. *Am J Cardiol* 2011;**108**:56–62.
- Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba follow-up study. *Am J Med* 1995;**98**:476–84.
- Watanabe H, Tanabe N, Watanabe T, Darbar D, Roden DM, Sasaki S et al. Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. *Circulation* 2008;**117**:1255–60.
- Schoen T, Pradhan AD, Albert CM, Conen D. Type 2 diabetes mellitus and risk of incident atrial fibrillation in women. *J Am Coll Cardiol* 2012;**60**:1421–8.
- Du X, Ninomiya T, de Galan B, Abadir E, Chalmers J, Pillai A et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. *Eur Heart J* 2009;**30**:1128–35.
- Aksnes TA, Schmieder RE, Kjeldsen SE, Ghani S, Hua TA, Julius S. Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial). *Am J Cardiol* 2008;**101**: 634–8.
- Gallagher C, Hendriks JM, Mahajan R, Middeldorp ME, Elliott AD, Pathak RK et al. Lifestyle management to prevent and treat atrial fibrillation. *Expert Rev Cardiovasc Ther* 2016;**14**:799–809.
- Nichols GA et al. Independent contribution of diabetes to increased prevalence and incidence of atrial fibrillation. *Diabetes Care* 2009;**32**:1851–6.
- Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Europace* 2016;**18**:1609–78.
- Freedman B, Camm J, Calkins H, Healey JS, Rosenqvist M, Wang J et al. Screening for atrial fibrillation: a report of the AF-SCREEN international collaboration. *Circulation* 2017;**135**:1851–67.
- Mairesse GH, Moran P, Van Gelder I, Elsner C, Rosenqvist M, Mant J et al. Screening for Atrial Fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Societat Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE). *Europace* 2017;**19**:1851–67.
- Zaccardi F, Khan H, Laukkanen JA. Diabetes mellitus and risk of sudden cardiac death: a systematic review and meta-analysis. *Int J Cardiol* 2014;**177**:535–7.
- Anselmino M, Matta M, D'Ascenzo F, Pappone C, Santinelli V, Bunch TJ et al. Catheter ablation of atrial fibrillation in patients with diabetes mellitus: a systematic review and meta-analysis. *Europace* 2015;**17**:1518–25.
- Bogossian H, Frommeyer G, Brachmann J, Lewalter T, Hoffman E, Kuck KH et al. Catheter ablation of atrial fibrillation and atrial flutter in patients with diabetes mellitus: who benefits and who does not? Data from German ablation registry. *Int J Cardiol* 2016;**214**:25–30.
- Forleo GB, Mantica M, De Luca L, Leo R, Santini L, Panigada S et al. Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy. *J Cardiovasc Electrophysiol* 2009;**20**:22.
- Jouven X, Lemaître RN, Rea TD, Sotoodehnia N, Empana JP, Siscovick DS. Diabetes, glucose level, and risk of sudden cardiac death. *Eur Heart J* 2005;**26**: 2142–7.
- Potpara T, Marinkovic-Eric J, Grujic M, Radojkovic-Cirovic B, Vujisic-Tesic B, Petrovic M. [Effect of diabetes mellitus in recovery and maintenance of sinus rhythm in patients with persistent atrial fibrillation]. *Srp Arh Celok Lek* 2002;**130**: 189–92.
- Kucharska-Newton AM, Couper DJ, Pankow JS, Prineas RJ, Rea TD, Sotoodehnia N et al. Diabetes and the risk of sudden cardiac death, the Atherosclerosis Risk in Communities study. *Acta Diabetol* 2010;**47**(Suppl 1): 161–8.
- Eranti A, Kerola T, Aro AL, Tikkanen JT, Rissanen HA, Anttonen O et al. Diabetes, glucose tolerance, and the risk of sudden cardiac death. *BMC Cardiovasc Disord* 2016;**16**:51.
- Cardoso CR, Salles GF, Deccache W. Prognostic value of QT interval parameters in type 2 diabetes mellitus: results of a long-term follow-up prospective study. *J Diabetes Complications* 2003;**17**:169–78.
- Molon G, Costa A, Bertolini L, Zenari L, Arcaro G, Barbieri E et al. Relationship between abnormal microvolt T-wave alternans and poor glycemic control in type 2 diabetic patients. *Pacing Clin Electrophysiol* 2007;**30**:1267–72.
- O'Brien IA, O'Hare JP, Lewin IG, Corral RJ. The prevalence of autonomic neuropathy in insulin-dependent diabetes mellitus: a controlled study based on heart rate variability. *Q J Med* 1986;**61**:957–67.
- Tsuji H, Venditti FJ Jr, Manders ES, Evans JC, Larson MG, Feldman CL et al. Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study. *Circulation* 1994;**90**:878–83.
- Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. *Circulation* 2007;**115**:387–97.
- Singh JP, Larson MG, O'Donnell CJ, Wilson PF, Tsuji H, Lloyd-Jones DM et al. Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). *Am J Cardiol* 2000;**86**:309–12.
- Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. *Cardiovasc Diabetol* 2014;**13**: 28.
- Balcioglu S, Arslan U, Turkoğlu S, Özdemir M, Çengel A. Heart rate variability and heart rate turbulence in patients with type 2 diabetes mellitus with versus without cardiac autonomic neuropathy. *Am J Cardiol* 2007;**100**:890–3.
- Miwa Y, Miyakoshi M, Hoshida K, Yanagisawa R, Abe A, Tsukada T et al. Heart rate turbulence can predict cardiac mortality following myocardial infarction in patients with diabetes mellitus. *J Cardiovasc Electrophysiol* 2011;**22**:1135–40.
- Bissinger A, Ruxer J, Ahmed RB, Lubinski A. Heart rate turbulence in patients with poorly controlled diabetes mellitus type 2. *Arch Med Sci* 2014;**10**:1073–7.

47. Piori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. *Europace* 2015;**17**: 1601–87.
48. Chen-Scarabelli C, Scarabelli TM. Suboptimal glycemic control, independently of QT interval duration, is associated with increased risk of ventricular arrhythmias in a high-risk population. *Pacing Clin Electrophysiol* 2006;**29**:9–14.
49. Secrest AM, Becker DJ, Kelsey SF, Laporte RE, Orchard TJ. Characterizing sudden death and dead-in-bed syndrome in Type 1 diabetes: analysis from two childhood-onset Type 1 diabetes registries. *Diabet Med* 2011;**28**: 293–300.
50. Tanenberg RJ, Newton CA, Drake AJ. Confirmation of hypoglycemia in the “dead-in-bed” syndrome, as captured by a retrospective continuous glucose monitoring system. *Endocr Pract* 2010;**16**:244–8.
51. NICE-SUGAR Study Investigators, Finfer S, Liu B, Chittock DR, Norton R, Myburgh JA et al. Hypoglycemia and risk of death in critically ill patients. *N Engl J Med* 2012;**367**:1108–18.
52. ORIGIN Trial Investigators, Mellbin LG, Ryden L, Riddle MC, Probstfield J, Rosenstock J et al. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. *Eur Heart J* 2013;**34**:3137–44.
53. Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr et al.; ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. *N Engl J Med* 2011;**364**:818–28.
54. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 2008;**358**: 2545–59.
55. Chow E, Bernjak A, Williams S, Fawdry RA, Hibbert S, Freeman J et al. Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. *Diabetes* 2014;**63**:1738–47.
56. Hay LC, Wilmschurst EG, Fulcher G. Unrecognized hypo- and hyperglycemia in well-controlled patients with type 2 diabetes mellitus: the results of continuous glucose monitoring. *Diabetes Technol Ther* 2003;**5**:19–26.
57. Reno CM, Daphna-Iken D, Chen YS, Vander Weele J, Jethi K, Fisher SJ. Severe hypoglycemia-induced lethal cardiac arrhythmias are mediated by sympathoadrenal activation. *Diabetes* 2013;**62**:3570–81.
58. Tsujimoto T, Sugiyama T, Shapiro MF, Noda M, Kajio H. Risk of cardiovascular events in patients with diabetes mellitus on beta-blockers. *Hypertension* 2017;**70**:103–10.
59. Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using beta-blockers: a critical review of the evidence. *J Am Coll Cardiol* 2007;**50**: 563–72.
60. American Diabetes A. 6. Glycemic targets. *Diabetes Care* 2017;**40**(Suppl 1): S48–56.
61. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med* 2015;**373**:2117–28.
62. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med* 2016;**375**:311–22.
63. American Diabetes A. 8. Pharmacologic approaches to glycemic treatment. *Diabetes Care* 2017;**40**(Suppl 1): S64–74.
64. Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S et al. Liraglutide and renal outcomes in type 2 diabetes. *N Engl J Med* 2017;**377**: 839–48.
65. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondou N et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med* 2017;**377**:644–57.
66. Raz I, Wiviott SD. Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58). ClinicalTrials.gov Identifier: NCT01730534.
67. Sonesson C, Johansson PA, Johnsson E, Gause-Nilsson I. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. *Cardiovasc Diabetol* 2016;**15**:37.
68. Wu JHY, Foote C, Blomster J, Toyama T, Perkovic V, Sundstrom J et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol* 2016;**4**:411–9.
69. Kalra S. Sodium-glucose cotransporter 2 (SGLT2)inhibitors and cardiovascular disease: a systematic review. *Cardiol Ther* 2016;**5**:161–8.
70. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. *N Engl J Med* 2017;**377**:1228–39.
71. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. *N Engl J Med* 2015;**373**:2247–57.
72. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2008;**358**:2560–72.
73. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD et al. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med* 2009;**360**:129–39.
74. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, Foster D et al. Intensive versus conventional glucose control in critically ill patients. *N Engl J Med* 2009;**360**:1283–97.
75. Chen YC, Chen SA, Chen YJ, Chang MS, Chan P, Lin CI. Effects of thyroid hormone on the arrhythmogenic activity of pulmonary vein cardiomyocytes. *J Am Coll Cardiol* 2002;**39**:366–7.
76. Zhang Y, Dedkov EI, Lee B 3rd, Li Y, Pun K, Gerdes AM. Thyroid hormone replacement therapy attenuates atrial remodeling and reduces atrial fibrillation inducibility in a rat myocardial infarction-heart failure model. *J Card Fail* 2014;**20**:1012–9.
77. Mangiardi L, Gaita F, Brun S, Presbitero P, Nademanee K, Singh BN. Atrioventricular block complicating amiodarone-induced hypothyroidism in a patient with pre-excitation and rate-dependent bilateral bundle branch block. *J Am Coll Cardiol* 1986;**7**:180–4.
78. Purcell K, Roepke TK, Abbot GW. Cardiac arrhythmias and thyroid dysfunction: a novel genetic link. *Int J Biochem Cell Biol* 2010;**42**:1767–70.
79. Galloway A, Li H, Vanderlinde-Wood M, Khan M, Benbrook A, Liles C et al. Activating autoantibodies to the β1/2-adrenergic and M2 muscarinic receptors associate with atrial tachyarrhythmias in patients with hyperthyroidism. *Endocrine* 2015;**49**:457–63.
80. Selmer C, Olesen JB, Hansen ML, Lindhardsen J, Schjerning Olsen AM, Clausager J et al. The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. *BMJ* 2012;**345**:e7895.
81. Frost L, Vestergaard P, Mosekilde L. Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study. *Arch Intern Med* 2004;**164**: 1675–8.
82. Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke JL et al. Thyroid status, cardiovascular risk and mortality in older adults. *JAMA* 2006;**295**:1033–41.
83. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P et al. Low serum thyrotropin concentrations as a risk factors for atrial fibrillation in older persons. *N Engl J Med* 1994;**331**:1249–52.
84. Auer J, Scheibner P, Mische T, Langsteiger W, Eber O, Eber B. Subclinical hypothyroidism as a risk factor for atrial fibrillation. *Am Heart J* 2001;**142**: 838–42.
85. Gammage MD, Parle JV, Holder RL, Roberts LM, Hobbs FDR, Wilson S et al. Association between free thyroxine concentration and atrial fibrillation. *Arch Intern Med* 2007;**167**:928–34.
86. Collet TH, Gussekloo J, Bauer DC, den Elzen WPJ, Wendy PJ, Cappola AR et al.; MAS for the Thyroid Studies Collaboration. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. *Arch Intern Med* 2012;**172**: 799–809.
87. Heeringa J, Hoogendoorn EH, van der Deure WM, Hofman A, Peeters RP, Hop WCJ et al. High-normal thyroid function and risk of atrial fibrillation. *Arch Intern Med* 2008;**168**:2219–24.
88. Floriani C, Gencer B, Collet TH, Rodondi N. Subclinical thyroid dysfunction and cardiovascular diseases: 2016 update. *Eur Heart J* 2017; doi: 10.1093/eurheartj/ehx050.
89. Gorennek B, Pelliccia A, Benjamin EJ, Boriani G, Crijs HJ, Fogel RI et al. European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). *Europace* 2017;**19**:190–225.
90. Kim EJ, Lyass A, Wang N, Massaro JM, Fox CS, Benjamin EJ et al. Relation of hypothyroidism and incident atrial fibrillation (from the Framingham Heart Study). *Am Heart J* 2014;**167**:123–6.
91. Brandt F, Thvilum M, Almind D, Christensen K, Green A, Hegedu L et al. Morbidity before and after the diagnosis of hyperthyroidism: a nationwide register-based study. *PLoS One* 2011;**8**:e66711.
92. Chauhan V. Hypothyroidism was 300% more frequent than hyperthyroidism in patients with atrial fibrillation enrolled over 10 years. *Am J Med* 2015;**128**: e51.
93. Martinez-Comendador J, Marcos-Vidal JM, Gualis J, Martin CE, Marin E, Otero J et al. Subclinical hypothyroidism might increase the risk of postoperative atrial fibrillation after aortic valve replacement. *Thorac Cardiovasc Surg* 2016;**64**: 427–33.
94. Jolobe OMP. Thyroid heart disease should include the coincidental association of hypothyroidism and atrial fibrillation. *Am J Med* 2015;**128**:e9.

95. Worku B, Tortolani AJ, Gulkarov I, Isom OW, Klein I. Preoperative hypothyroidism is a risk factor for postoperative atrial fibrillation in cardiac surgical patients. *J Card Surg* 2015;**30**:307–12.
96. Zhang Y, Dedkov EI, Teplitsky D, Weltman NY, Pol CJ, Rajagopalan V et al. Both hypothyroidism and hyperthyroidism increase atrial fibrillation inducibility in rats. *Circ Arrhythm Electrophysiol* 2013;**6**:952–9.
97. Kolettis TM, Tsatsoulis A. Subclinical hypothyroidism: an overlooked cause of atrial fibrillation? *J Atr Fibrillation* 2012;**5**:710.
98. Nakazawa HK, Sakurai K, Hamada N, Momotani N, Ito K. Management of atrial fibrillation in the post-thyrototoxic state. *Am J Med* 1982;**72**:903–6.
99. Zhou ZH, Ma LL, Wang LX. Risk factors for persistent atrial fibrillation following successful hyperthyroidism treatment with radioiodine therapy. *Intern Med* 2011;**50**:2947–51.
100. Tsybaliuk I, Unukovych D, Shvets N, Dinets A. Cardiovascular complications secondary to Graves' disease: a prospective study from Ukraine. *PLoS One* 2015;**10**:e0122388.
101. Gauthier JM, Mohamed HE, Noureldine SI, Nazari-Shafti TZ, Thethi TK, Kandil E. Impact of thyroidectomy on cardiac manifestations of Graves' disease. *Laryngoscope* 2016;**126**:1256–9.
102. Feely J, Peden N. Use of beta-adrenoreceptor blocking drugs in hyperthyroidism. *Drugs* 1984;**27**:425–46.
103. Jansson S, Lie-Karlson K, Stenqvist O, Körner U, Lundholm K, Tisell LE. Oxygen consumption in patients with hyperthyroidism before and after treatment with beta-blockade vs. thyrostatic treatment: a prospective randomized study. *Ann Surg* 2001;**233**:60–4.
104. Dalan R, Leow MK, Leow MC, Leow M. Cardiovascular collapse associated with beta-blockade in thyroid storm. *Exp Clin Endocrinol Diabetes* 2007;**115**:392–6.
105. Nakazawa HK, Handa S, Nakamura Y, Oyanagi H, Hasegawa M, Ishikawa N et al. High maintenance rate of sinus rhythm after cardioversion in post-thyrototoxic chronic atrial fibrillation. *Int J Cardiol* 1987;**16**:47–55.
106. Nakazawa H, Lythall DA, Noh J, Ishikawa N, Sugino K, Ito K et al. Is there a place for the late cardioversion of atrial fibrillation? A long-term follow-up study of patients with post-thyrototoxic atrial fibrillation. *Eur Heart J* 2000;**21**:327–33.
107. Siu C-W, Jim M-H, Zhang X, Chan Y-H, Pong V, Kwok J et al. Comparison of atrial fibrillation recurrence rates after successful electrical cardioversion in patients with hyperthyroidism-induced versus non-hyperthyroidism-induced persistent atrial fibrillation. *Am J Cardiol* 2009;**103**:540–3.
108. Ma CS, Liu X, Hu FL, Dong JZ, Liu XP, Wang XH. Catheter ablation of atrial fibrillation in patients with hyperthyroidism. *J Interv Card Electrophysiol* 2007;**18**:137–42.
109. Machino T, Tada H, Sekiguchi Y, Yamasaki H, Kuroki K, Igarashi M. Prevalence and influence of hyperthyroidism on the long-term outcome of catheter ablation for drug-refractory atrial fibrillation. *Circ J* 2012;**76**:2546–51.
110. Wongcharoen W, Lin YJ, Chang SL, Lo LW, Hu YF, Chung FP. History of hyperthyroidism and long-term outcome of catheter ablation of drug-refractory atrial fibrillation. *Heart Rhythm* 2015;**12**:1956–62.
111. Chan PH, Hai J, Yeung CY, Lip GY, Lam KS, Tse HF et al. Benefit of anticoagulation therapy in hyperthyroidism-related atrial fibrillation. *Clin Cardiol* 2015;**38**:476–82.
112. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. *Eur Heart J* 2012;**33**:1500–10.
113. Petersen P, Hansen JM. Stroke in thyrotoxicosis with atrial fibrillation. *Stroke* 1988;**19**:15–8.
114. Bruere H, Fauchier L, Bernard Brunet A, Pierre B, Simeon E, Babuty D et al. History of thyroid disorders in relation to clinical outcomes in atrial fibrillation. *Am J Med* 2015;**128**:30–7.
115. von Olshausen K, Bischoff S, Kahaly G, Mohr-Kahaly S, Erbel R, Beyer J et al. Cardiac arrhythmias and heart rate in hyperthyroidism. *Am J Cardiol* 1989;**63**:930–3.
116. Kulairi Z, Deol N, Tolly R, Manocha R, Naseer M. QT prolongation due to Graves' disease. *Case Rep Cardiol* 2017;**2017**:1.
117. Kobayashi H, Haketa A, Abe M, Tahira K, Hatanaka Y, Tanaka S et al. Unusual manifestation of Graves' disease: ventricular fibrillation. *Eur Thyroid J* 2015;**4**:207–12.
118. Ozcan KS, Osmonov D, Erdinler I, Altay S, Yildirim E, Turkkan C et al. Atrioventricular block in patients with thyroid dysfunction: prognosis after treatment with hormone supplementation or antithyroid medication. *J Cardiol* 2012;**60**:327–32.
119. Namura M, Kanaya H, Lkeda M, Shibayama S, Ohka T. Hyperthyroidism complicated with sick sinus syndrome. *Jpn Circ J* 1995;**59**:824–8.
120. Kannan L, Kotus-Bart J, Amanullah A. Prevalence of cardiac arrhythmias in hypothyroid and euthyroid patients. *Horm Metab Res* 2017;**49**:430–3.
121. Lim CH, Lim P. Recurrent ventricular tachycardia in hypothyroidism. *Aust N Z J Med* 1976;**6**:68–70.
122. Fredlund BO, Olsson SB. Long QT interval and ventricular tachycardia of "torsade de pointe" type in hypothyroidism. *Acta Med Scand* 1983;**213**:231–5.
123. Kukla P, Szczuka K, Słowiak-Lewińska T, Bromblik A, Hajduk B, Kluczewski M. Acquired long QT syndrome with torsade de pointes in a patient with primary hypothyroidism. *Kardiologia Pol* 2003;**58**:224–6.
124. Schenck JB, Rizvi AA, Lin T. Severe primary hypothyroidism manifesting with torsades de pointes. *Am J Med Sci* 2006;**331**:154–6.
125. Kandan SR, Saha M. Severe primary hypothyroidism presenting with torsades de pointes. *BMJ Case Rep* 2012;**2012**:bcr1220115306. doi: 10.1136/bcr.2011.5306.
126. Ellis CR, Murray KT. When an ICD is not the answer... Hypothyroidism-induced cardiomyopathy and torsades de pointes. *J Cardiovasc Electrophysiol* 2008;**19**:1105–7.
127. Rosengarten M, Brooks R. Torsade de pointes ventricular tachycardia in a hypothyroid patient treated with propafenone. *Can J Cardiol* 1987;**3**:234–9.
128. Pedersen CT, Kay GN, Kalman J, Borggreve M, Della-Bella P, Dickfeld T et al. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. *Europace* 2014;**16**:1257–83.
129. Esposito F, Liguori V, Maresca G, Cerrone A, De Filippo O, Trimarco B et al. Subclinical hypothyroidism: a reversible cause of complete loss of ventricular lead capture. *Circ Arrhythm Electrophysiol* 2014;**7**:182–4.
130. Schlesinger Z, Rosenberg T, Stryer D, Gilboa Y. Exit block in myxedema, treated effectively by thyroid hormone therapy. *Pacing Clin Electrophysiol* 1980;**3**:737–9.
131. Patton KK, Levy M, Viswanathan M. Atrial lead dysfunction: an unusual feature of hypothyroidism. *Pacing Clin Electrophysiol* 2008;**31**:1650–2.
132. Basu D, Chatterjee K. Unusually high pacemaker threshold in severe myxedema. Decrease with thyroid hormone therapy. *Chest* 1976;**70**:677–9.
133. Lardoux H, Cenac A, Perlemuter L, Bernheim R, Hazard J. Disorders of intra-cardiac conduction and hypothyroidism in adults. A systematic study of 42 cases. *Nouv Presse Med* 1975;**4**:1859–62.
134. Numata T, Abe H, Terao T, Nakashima Y. Possible involvement of hypothyroidism as a cause of lithium-induced sinus node dysfunction. *Pacing Clin Electrophysiol* 1999;**22**:954–7.
135. Blanco VM, Moller I, Castano G, Casares G. Reversible sick sinus syndrome and hypothyroidism due to lithium. *Med Clin (Barc)* 2003;**120**:478–9.
136. Schantz ET, Dubbs AW. Complete auriculoventricular block in myxedema with reversion to normal sinus rhythm on thyroid therapy. *Am Heart J* 1951;**41**:613–9.
137. Chatzitomaris A, Scheeler M, Gotzmann M, Köditz R, Schildroth J, Knyhala KM et al. Second degree AV block and severely impaired contractility in cardiac myxedema: a case report. *Thyroid Res* 2015;**8**:6.
138. Seol SH, Kim DI, Park BM, Kim DK, Song PS, Jin HY et al. Complete atrioventricular block presenting with syncope caused by severe hypothyroidism. *Cardiol Res* 2012;**3**:239–41.
139. Schoenmakers N, de Graaff WE, Peters RH. Hypothyroidism as the cause of atrioventricular block in an elderly patient. *Neth Heart J* 2008;**16**:57–9.
140. Nakayama Y, Ohno M, Yonemura S, Uozumi H, Kobayakawa N, Fukushima K et al. A case of transient 2:1 atrioventricular block, resolved by thyroxine supplementation for subclinical hypothyroidism. *Pacing Clin Electrophysiol* 2006;**29**:106–8.
141. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). *Europace* 2013;**15**:1070–118.
142. Jabrocka-Hybel A, Bednarczuk T, Bartalena L, Pach D, Ruchała M, Kamiński G et al. Amiodarone and the thyroid. *Endokrynol Pol* 2015;**66**:176–96.
143. Bogazzi F, Bartalena L, Martino E. Approach to the patient with amiodarone-induced thyrotoxicosis. *J Clin Endocrinol Metab* 2010;**95**:2529–35.
144. De Leo S, Lee SY, Braverman LE. Hyperthyroidism. *Lancet* 2016;**388**:906–18.
145. Vassallo P, Trohman RC. Prescribing amiodarone an evidence-based review of clinical indications. *JAMA* 2007;**298**:1312–22.
146. Barbesino G, Tomer Y. Clinical Utility of TSH Receptor Antibodies. *J Clin Endocrinol Metab* 2013;**98**:2247–55.
147. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. *Thyroid* 2016;**26**:1343–421.
148. Benjamins S, Dullaart RPF, Sluiter WJ, Rienstra M, van Gelder IC, Links TP. The clinical value of regular thyroid function tests during amiodarone treatment. *Eur J Endocrinol* 2017;**177**:9–14.
149. Piccini JP, Berger JS, O'Connor CM. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. *Eur Heart J* 2009;**30**:1245–53.
150. Vorperian VR, Havighurst TC, Miller S, January CR. Adverse effects of low dose amiodarone: a meta-analysis. *J Am Coll Cardiol* 1997;**30**:791–8.

151. Batcher EL, Tang XC, Singh BN, Singh SN, Reda DJ, Hershman JM; SAFE-T Investigators. Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation. *Am J Med* 2007;**120**:880–5.
152. Ross IL, Marshall D, Okreglicki A, Isaacs S, Levitt NS. Amiodarone-induced thyroid dysfunction. *S Afr Med J* 2005;**95**:180–3.
153. Ahmed S, Van Gelder IC, Wiesfeld AC, Van Veldhuisen DJ, Links TP. Determinants and outcome of amiodarone-associated thyroid dysfunction. *Clin Endocrinol (Oxf)* 2011;**75**:388–94.
154. Lee CH, Nam G-B, Park H-G, Kim HY, Park K-M, Kim J et al. Effects of antiarrhythmic drugs on inappropriate shocks in patients with implantable cardioverter defibrillators. *Circ J* 2008;**72**:102–5.
155. Kinoshita S, Hayashi T, Wada K, Yamato M, Kuwahara T, Anzai T et al. Risk factors for amiodarone-induced thyroid dysfunction in Japan. *J Arrhythm* 2016;**32**:474–80.
156. Shiga T, Wakaumi M, Matsuda N, Shoda M, Hagiwara N, Sato K et al. Amiodarone-induced thyroid dysfunction and ventricular tachyarrhythmias during long-term therapy in Japan. *Jpn Circ J* 2001;**65**:958–60.
157. Pillarisetti J, Vanga SR, Lakireddy D. Amiodarone induced thyrotoxicosis—fluctuating RVOT and LV scar VT. *J Atr Fibrillation* 2013;**5**:7–9.
158. Mun H-S, Shen C, Pak H-N, Lee M-H, Lin S-F, Chen P-S et al. Chronic amiodarone therapy impairs the function of the superior sinoatrial node in patients with atrial fibrillation. *Circ J* 2013;**77**:2255–63.
159. Cracana I, Vasilcu TF, Mardare A, Alexa ID, Marcu DT. Severe amiodarone-induced bradycardia conceals sick sinus syndrome: case report. *Rev Med Chir Soc Med Nat Iasi* 2016;**120**:110–3.
160. Essebag V, Hadjis T, Platt RW, Pilote L. Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction. *J Am Coll Cardiol* 2003;**41**:249–54.
161. Czarnywojtek A, Plazinska MT, Zgorzalewicz-Stachowiak M, Wolinski K, Stangierski A, Miechowicz I et al. Dysfunction of the thyroid gland during amiodarone therapy: a study of 297 cases. *Ther Clin Risk Manag* 2016;**12**:505–13.
162. Hermida JS, Tchong E, Jarry G, Moullart V, Arlot S, Rey JL et al. Radioiodine ablation of the thyroid to prevent recurrence of amiodarone-induced thyrotoxicosis in patients with resistant tachyarrhythmias. *Europace* 2004;**6**:169–74.
163. UK Guidelines for the Use of Thyroid Function Tests. 2002. www.british-thyroid-association.org (15 December 2017, date last accessed).
164. Diederichsen SZ, Darkner S, Chen X, Johannesen A, Pehrson S, Hansen J et al. Short-term amiodarone treatment for atrial fibrillation after catheter ablation induces a transient thyroid dysfunction: results from the placebo-controlled, randomized AMIO-CAT trial. *Eur J Intern Med* 2016;**33**:36–41.
165. Hudzik B, Zubelewicz-Szkodzincka B. Amiodarone-related thyroid dysfunction. *Intern Emerg Med* 2014;**9**:829–39.
166. Zelinka T, Petrak O, Turkova H, Holaj R, Strauch B, Krsek M et al. High incidence of cardiovascular complications in pheochromocytoma. *Horm Metab Res* 2012;**44**:379–84.
167. Prejbisz A, Lenders JWM, Eisenhofer G, Januszewicz A. Cardiovascular manifestations of pheochromocytoma. *J Hypertens* 2011;**29**:2049–60.
168. Dabrowska B, Pruszczyk P, Dabrowski A, Feltynowski T, Wociał B, Januszewicz W. Influence of alpha-adrenergic blockade on ventricular arrhythmias, QTc interval and heart rate variability in pheochromocytoma. *J Hum Hypertens* 1995;**9**:925–9.
169. Traykov VB, Kotirkov KI, Petrov IS. Pheochromocytoma presenting with bidirectional ventricular tachycardia. *Heart* 2013;**99**:509.
170. Brouwers FM, Eisenhofer G, Lenders JWM, Pacak K. Emergencies caused by pheochromocytoma, neuroblastoma, or ganglioneuroma. *Endocrinol Metab Clin North Am* 2006;**35**:699–724.
171. Galetta F, Franzoni F, Bernini G, Poupak F, Carpi A, Cini G et al. Cardiovascular complications in patients with pheochromocytoma: a mini-review. *Biomed Pharmacother* 2010;**64**:505–9.
172. Manger WM, Gifford RW. Pheochromocytoma. *J Clin Hypertens (Greenwich)* 2002;**4**:62–72.
173. Tewari P, Sikora R. Hypertension and tachycardia during adrenal manipulation. *Can J Anaesth* 1995;**42**:417–9.
174. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. *Endocr Rev* 2004;**25**:102–52.
175. McCabe J, Ayuk J, Sherlock M. Treatment factors that influence mortality in acromegaly. *Neuroendocrinology* 2016;**103**:66–74.
176. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. *J Clin Endocrinol Metab* 2008;**93**:61–7.
177. Katznelson L, Laws ER, Melmed S, Molitch ME, Murad MH, Utz A et al. Acromegaly: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab* 2014;**99**:3933–51.
178. Ritvoonen E, Loytyniemi E, Jaatinen P, Ebeling T, Moilanen L, Nuutila P et al. Mortality in acromegaly: a 20-year follow-up study. *Endocr Relat Cancer* 2016;**23**:469–80.
179. Bihan H, Espinosa C, Valdes-Socin H, Salenave S, Young J, Levasseur S et al. Long-term outcome of patients with acromegaly and congestive heart failure. *J Clin Endocrinol Metab* 2004;**89**:5308–13.
180. dos Santos Silva CM, Gottlieb I, Volschan I, Kasuki L, Warszawski L, Balarini Lima GA et al. Low frequency of cardiomyopathy using cardiac magnetic resonance imaging in an acromegaly contemporary cohort. *J Clin Endocrinol Metab* 2015;**100**:4447–55.
181. Herrmann BL, Bruch C, Saller B, Ferdin S, Dages N, Ose C et al. Occurrence of ventricular late potentials in patients with active acromegaly. *Clin Endocrinol (Oxf)* 2001;**55**:201–7.
182. Lie JT, Grossman SJ. Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. *Am Heart J* 1980;**100**:41–52.
183. Frustaci A, Chimenti C, Setoguchi M, Guerra S, Corsello S, Crea F et al. Cell death in acromegalic cardiomyopathy. *Circulation* 1999;**99**:1426–34.
184. Rossi E, Zuppi P, Pennestri F, Biasucci LM, Lombardo A, De Marinis L et al. Acromegalic cardiomyopathy. Left ventricular filling and hypertrophy in active and surgically treated disease. *Chest* 1992;**102**:1204–8.
185. Lombardi G, Galdiero M, Auriemma RS, Pivonello R, Colao A. Acromegaly and the cardiovascular system. *Neuroendocrinology* 2006;**83**:211–7.
186. Clayton RN. Cardiovascular function in acromegaly. *Endocr Rev* 2003;**24**:272–7.
187. Hayward RP, Emanuel RW, Nabarro JD. Acromegalic heart disease: influence of treatment of the acromegaly on the heart. *Q J Med* 1987;**62**:41–58.
188. Kahaly G, Olshausen KV, Mohr-Kahaly S, Erbel R, Boor S, Beyer J et al. Arrhythmia profile in acromegaly. *Eur Heart J* 1992;**13**:51–6.
189. Surawicz B, Mangiardi ML. Electrocardiogram in endocrine and metabolic disorders. *Cardiovasc Clin* 1977;**8**:243–66.
190. Marin F, Pico AM, Martinez JG, Domínguez JR, Alfayate R, Sogorb F. Heart disease in acromegaly. Study of 27 patients. *Med Clin (Barc)* 1996;**107**:326–30.
191. Rodrigues EA, Caruana MP, Lahiri A, Nabarro JD, Jacobs HS, Raftery EB. Subclinical cardiac dysfunction in acromegaly: evidence for a specific disease of heart muscle. *Br Heart J* 1989;**62**:185–94.
192. Maffei P, Martini C, Milanesi A, Corfini A, Mioni R, de Carlo E et al. Late potentials and ventricular arrhythmias in acromegaly. *Int J Cardiol* 2005;**104**:197–203.
193. Matturri L, Varesi C, Nappo A, Cuttin MS, Rossi L. Sudden cardiac death in acromegaly. Anatomopathological observation of a case. *Minerva Med* 1998;**89**:287–91.
194. Rossi L, Thiene G, Caragaro L, Giordano R, Lauro S. Dysrhythmias and sudden death in acromegalic heart disease. A clinicopathologic study. *Chest* 1977;**72**:495–8.
195. Doimo S, Miani D, Finato N, Driussi M, Sinagra G, Livi U et al. Acromegalic cardiomyopathy with malignant arrhythmogenic pattern successfully treated with mechanical circulatory support and heart transplantation. *Can J Cardiol* 2017;**33**:830 e9–e11.
196. Unbul M, Eryilmaz U, Guney E, Ture M, Akgullu C. QT dispersion in patients with acromegaly. *Endocrine* 2013;**43**:419–23.
197. Baser H, Akar Bayram N, Polat B, Evranos B, Ersoy R, Bozkurt E et al. The evaluation of QT intervals during diagnosis and after follow-up in acromegaly patients. *Acta Med Port* 2014;**27**:428–32.
198. Warszawski L, Kasuki L, Sa R, Dos Santos Silva CM, Volschan I, Gottlieb I et al. Low frequency of cardiac arrhythmias and lack of structural heart disease in medically-naïve acromegaly patients: a prospective study at baseline and after 1 year of somatostatin analogs treatment. *Pituitary* 2016;**19**:582–9.
199. Lombardi G, Colao A, Marzullo P, Biondi B, Palmieri E, Fazio S. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study. *J Endocrinol Invest* 2002;**25**:971–6.
200. Auriemma RS, Pivonello R, De Martino MC, Cudemo G, Grasso LF, Galdiero M et al. Treatment with GH receptor antagonist in acromegaly: effect on cardiac arrhythmias. *Eur J Endocrinol* 2012;**168**:15–22.
201. Mercado M, Gonzalez B, Vargas G, Ramirez C, de los Monteros AL, Sosa E et al. Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. *J Endocrinol Metab* 2014;**99**:4438–46.
202. Horner JM, Thorsson AV, Hintz R. Growth deceleration patterns in children with constitutional short stature: an aid to diagnosis. *Pediatrics* 1978;**62**:529–34.
203. Ascoli P, Cavagnini F. Hypopituitarism. *Pituitary* 2006;**9**:335–42.
204. Simsek Y, Kaya MG, Tanriverdi B, Çalpakporur B, Diri H, Karaca Z et al. Evaluation of long-term pituitary functions in patients with severe ventricular arrhythmia: a pilot study. *J Endocrinol Invest* 2014;**37**:1057–64.
205. Okada T, Tomoda T, Shinohara M, Misaki Y, Shiraishi T, Fujieda M et al. Atrioventricular block in a patient with growth hormone deficiency during growth hormone therapy. *Pediatr Int* 1999;**41**:90–3.
206. Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. *Am J Surg* 1964;**107**:159–72.

207. Lim JS, Park S, Park SI, Oh YT, Choi E, Kim JY *et al*. Cardiac dysfunction in association with increased inflammatory markers in primary aldosteronism. *Endocrinol Metab (Seoul)* 2016;**31**:567–76.
208. Iravanian S, Dudley SC Jr. The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias. *Heart Rhythm* 2008;**5**:S12–7.
209. Sechi LA, Colussi G, Di Fabio A, Catena C. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. *Am J Hypertens* 2010;**23**:1253–60.
210. Catena C, Colussi G, Nait F, Martinis F, Pezzutto F, Sechi LA. Aldosterone and the heart: still an unresolved issue? *Front Endocrinol (Lausanne)* 2014;**5**:168.
211. Rhee SS, Pearce EN. Update: systemic Diseases and the Cardiovascular System (II). The endocrine system and the heart: a review. *Rev Esp Cardiol* 2011;**64**:220–31.
212. Milliez P, Gierard X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. *J Am Coll Cardiol* 2005;**45**:1243–8.
213. Mihailidou AS. Aldosterone in heart disease. *Curr Hypertens Rep* 2012;**14**:125–9.
214. He BJ, Anderson ME. Aldosterone and cardiovascular disease: the heart of the matter. *Trends Endocrinol Metab* 2013;**24**:21–30.
215. Stowasser M. New perspectives on the role of aldosterone excess in cardiovascular disease. *Clin Exp Pharmacol Physiol* 2001;**28**:783–91.
216. Weiss JN, Qu Z, Shivkumar K. Electrophysiology of hypokalemia and hyperkalemia. *Circ Arrhythm Electrophysiol* 2017;**10**:e004667.
217. Seccia TM, Caroccia B, Adler GK, Maiolino G, Cesari M, Rossi GP. Arterial hypertension, atrial fibrillation, and hyperaldosteronism: the triple trouble. *Hypertension* 2017;**69**:545–50.
218. Zelinka T, Holaj R, Petrak O, Strauch B, Kasalicky M, Hanus T *et al*. Life-threatening arrhythmia caused by primary aldosteronism. *Med Sci Monit* 2009;**15**:CS174–7.
219. Porodko M, Auer J, Eber B. Conn's syndrome and atrial fibrillation. *Lancet* 2001;**357**:1293–4.
220. Watson T, Karthikeyan VJ, Lip GY, Beevers DG. Atrial fibrillation in primary aldosteronism. *J Renin Angiotensin Aldosterone Syst* 2009;**10**:190–4.
221. Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A *et al*. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. *J Clin Endocrinol Metab* 2013;**98**:4826–33.
222. Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, Lorenz R *et al*. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. *J Clin Endocrinol Metab* 2009;**94**:1125–30.
223. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ *et al*. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2016;**37**:2129–200.
224. Sade E, Oto A, Oto A, Oner Z, Daver A, Onalan O *et al*. Adrenal adenoma presenting with torsade de pointes—a case report. *Angiology* 2002;**53**:471–4.
225. Geist M, Dorian P, Davies T, Greene M, Newman D. Hyperaldosteronism and sudden cardiac death. *Am J Cardiol* 1996;**78**:605–6.
226. Aydin A, Okmen E, Erdinler I, Sanli A, Cam N. Adrenal adenoma presenting with ventricular fibrillation. *Tex Heart Inst J* 2005;**32**:85–7.
227. Petramala L, Savoriti C, Zinamosca L, Marinelli C, Settevendemmie A, Calvieri C *et al*. Primary aldosteronism with concurrent primary hyperparathyroidism in a patient with arrhythmic disorders. *Intern Med* 2013;**52**:2071–5.
228. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R *et al*. Cardiovascular outcomes in patients with primary aldosteronism after treatment. *Arch Intern Med* 2008;**168**:80–5.
229. Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. *Hypertension* 2013;**62**:331–6.
230. Charmandari E, Nicolaidis NC, Chrousos GP. Adrenal insufficiency. *Lancet* 2014;**383**:2152–67.
231. Schumack MM, Larsen TR, Sane DC. Cardiac manifestations of adrenal insufficiency. *Rev Cardiovasc Med* 2016;**17**:131–6.
232. Mozolevska V, Schwartz A, Cheung D, Shaikh B, Bhagirath KM, Jassal DS. Addison's disease and dilated cardiomyopathy: a case report and review of the literature. *Case Rep Cardiol* 2016;**2016**:1.
233. Fallo F, Betterle C, Budano S, Lupia M, Boscaro M, Sonino N. Regression of cardiac abnormalities after replacement therapy in Addison's disease. *Eur J Endocrinol* 1999;**140**:425–8.
234. Ikegami Y, Fukuda T, Jo R, Momiyama Y. Reversible cardiomyopathy accompanied by secondary adrenal insufficiency. *Circ Heart Fail* 2016;**9**:e002919.
235. Singh G, Manickam A, Sethuraman M, Rathod RC. Takotsubo cardiomyopathy in a patient with pituitary adenoma and secondary adrenal insufficiency. *Indian J Crit Care Med* 2015;**19**:731–4.
236. Somerville W. The effect of cortisone on the cardiogram in chronic adrenal insufficiency. *Br Med J* 1950;**2**:860–2.
237. Nishizawa S, Nakamura T, Hamaoka T, Matsumuro A, Sawada T, Matsubara H. Lethal arrhythmia and corticosteroid insufficiency. *Am J Emerg Med* 2009;**27**:1167 e1–3.
238. Kanamori K, Yamashita R, Tsutsui K, Hara M, Murakawa Y. Long QT syndrome associated with adrenal insufficiency in a patient with isolated adrenocorticotrophic hormone deficiency. *Intern Med* 2014;**53**:2329–31.
239. Ozcan F, Ustun I, Berker D, Aydin Y, Delibas T, Guler S. Inverted T waves in patient with Addisonian crisis. *J Natl Med Assoc* 2005;**97**:1539–40.
240. Dogan M, Ertem AG, Cimen T, Yeter E. Type-1 Brugada-like ECG pattern induced by adrenal crisis. *Herz* 2015;**40**:304–6.
241. Komuro J, Kaneko M, Ueda K, Nitta S, Kasao M, Shirai T. Adrenal insufficiency causes life-threatening arrhythmia with prolongation of QT interval. *Heart Vessels* 2016;**31**:1003–5.
242. Rentoukas E, Lazaros G, Sotiropoulos S, Athanassiou M, Tsiachris D, Deftereos S *et al*. Extreme but not life-threatening QT interval prolongation? Take a closer look at the neck! *J Electrocardiol* 2013;**46**:128–30.
243. Çakkerli L, Husi G, Minxuri D, Roko E, Vyshka G. Primary hypoparathyroidism presenting with heart failure and ventricular fibrillation. *Oxf Med Case Reports* 2014;**2014**:77–9.
244. Lind L, Ljunghall S. Serum calcium and the ECG in patients with primary hyperparathyroidism. *J Electrocardiol* 1994;**27**:99–103.
245. Voss DM, Drake EH. Cardiac manifestations of hyperparathyroidism, with presentation of a previously unreported arrhythmia. *Am Heart J* 1967;**73**:235–9.
246. Chadli MC, Chaieb L, Jenni L, Chatti N, Allegue M, Zebidi A *et al*. Bigeminal arrhythmia associated with hyperparathyroid crisis. *Cmaj* 1988;**138**:1115–6.
247. Chang CJ, Chen SA, Tai CT, Yu WC, Chen YJ, Tsai CF *et al*. Ventricular tachycardia in a patient with primary hyperparathyroidism. *Pacing Clin Electrophysiol* 2000;**23**:534–7.
248. Kolb C, Lehmann G, Schreieck J, Ndrepepa G, Schmitt C. Storms of ventricular tachyarrhythmias associated with primary hyperparathyroidism in a patient with dilated cardiomyopathy. *Int J Cardiol* 2003;**87**:115–6.
249. Vestergaard P, Møllerup CL, Frøkjær VG, Christiansen P, Blichert-Toft M, Mosekilde L. Cardiovascular events before and after surgery for primary hyperparathyroidism. *World J Surg* 2003;**27**:216–22.
250. Hedbäck G, Odén A, Tisell LE. The influence of surgery on the risk of death in patients with primary hyperparathyroidism. *World J Surg* 1991;**15**:399–405.
251. Pepe J, Curione M, Morelli S, Varrenti M, Cammarota C, Cilli M *et al*. Parathyroidectomy eliminates arrhythmic risk in primary hyperparathyroidism, as evaluated by exercise test. *Eur J Endocrinol* 2013;**169**:255–61.
252. Speakman MT, Kloner RA. Viagra and cardiovascular disease. *Cardiovasc Pharmacol Therapeut* 1999;**4**:269–71.
253. Occhetta E, Bortnik M, Magnani A, Francalacci G, Vassanelli C. Primary hyperparathyroidism and arrhythmic storm in a patient with an implantable cardioverter defibrillator for primary prevention of sudden death. *Europace* 2004;**6**:184–8.
254. Di Fusco SA, Palazzo S, Colivicchi F, Santini M. World Society of Arrhythmias. The influence of gender on heart rhythm disease. *Pacing Clin Electrophysiol* 2014;**37**:650–7.
255. Tadros R, Ton AT, Fiset C, Nattel S. Sex differences in cardiac electrophysiology and clinical arrhythmias: epidemiology, therapeutics, and mechanisms. *Can J Cardiol* 2014;**30**:783–92.
256. Curtis AB, Narasimha D. Arrhythmias in women. *Clin Cardiol* 2012;**35**:166–71.
257. Jonsson MK, Vos MA, Duker G, Demolombe S, van Veen TA. Gender disparity in cardiac electrophysiology: implications for cardiac safety pharmacology. *Pharmacol Ther* 2010;**127**:9–18.
258. Gaborit N, Varro A, Le Bouter S, Szuts V, Escande D, Nattel S *et al*. Gender-related differences in ion-channel and transporter subunit expression in non-diseased human hearts. *J Mol Cell Cardiol* 2010;**49**:639–46.
259. Surawicz B, Parikh SR. Prevalence of male and female patterns of early ventricular repolarization in the normal ECG of males and females from childhood to old age. *J Am Coll Cardiol* 2002;**40**:1870–6.
260. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. *JAMA* 1993;**270**:2590–7.
261. Tisdale JE, Jaynes HA, Overholser BR, Sowinski KM, Flockhart DA, Kovacs RJ. Influence of oral progesterone administration on drug-induced qt interval lengthening: a randomized, double-blind, placebo-controlled crossover study. *JACC Clin Electrophysiol* 2016;**2**:765–74.
262. Locati EH, Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Lehmann MH *et al*. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. *Circulation* 1998;**97**:2237–44.
263. Seth R, Moss AJ, McNitt S, Zareba W, Andrews ML, Qi M *et al*. Long QT syndrome and pregnancy. *J Am Coll Cardiol* 2007;**49**:1092–8.

264. Rodriguez L-M, de Chillou C, Schläpfer J, Metzger J, Baiyan X, van den Dool A et al. Age at onset and gender of patients with different types of supraventricular tachycardias. *Am J Cardiol* 1992;**70**:1213–5.
265. Silversides CK, Harris L, Haberer K, Sermer M, Colman JM, Siu SC. Recurrence rates of arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on fetal and neonatal outcomes. *Am J Cardiol* 2006;**97**:1206–12.
266. Lip GY, Nieuwlaar R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart survey on atrial fibrillation. *Chest* 2010;**137**:263–72.
267. Pisters R, Lane DA, Nieuwlaar R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation. *Chest* 2010;**138**:1093–100.
268. Pisters R, Lane DA, Marin F, Camm AJ, Lip GY. Stroke and thromboembolism in atrial fibrillation. *Circ J* 2012;**76**:2289–304.
269. Overvad TF, Skjoth F, Lip GY, Lane DA, Albertsen IE, Rasmussen LH et al. Duration of diabetes mellitus and risk of thromboembolism and bleeding in atrial fibrillation: nationwide cohort study. *Stroke* 2015;**46**:2168–74.
270. Ashburner JM, Go AS, Chang Y, Fang MC, Fredman L, Applebaum KM et al. Effect of diabetes and glycemic control on ischemic stroke risk in AF patients: aTRIA study. *J Am Coll Cardiol* 2016;**67**:239–47.
271. Lip GY, Clementy N, Pierre B, Boyer M, Fauchier L. The impact of associated diabetic retinopathy on stroke and severe bleeding risk in diabetic patients with atrial fibrillation: the Loire Valley atrial fibrillation project. *Chest* 2015;**147**:1103–10.
272. Lega JC, Bertolotti L, Gremillet C, Chapelle C, Mismetti P, Cucherat M et al. Consistency of safety and efficacy of new oral anticoagulants across subgroups of patients with atrial fibrillation. *PLoS One* 2014;**9**:e91398.
273. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. *Chest* 2013;**144**:1555–63.
274. Lip GYH, Freedman B, De Caterina R, Potpara TS. Stroke prevention in atrial fibrillation: past, present and future. Comparing the guidelines and practical decision-making. *Thromb Haemostasis* 2017;**117**:1230–9.
275. Tang RB, Liu DL, Dong JZ, Liu XP, Long DY, Yu RH et al. High-normal thyroid function and risk of recurrence of atrial fibrillation after catheter ablation. *Circ J* 2010;**74**:1316–21.
276. Sousa PA, Providencia R, Albenque JP, Khoeiry Z, Combes N, Combes S et al. Impact of free thyroxine on the outcomes of left atrial ablation procedures. *Am J Cardiol* 2015;**116**:1863–8.
277. Kim KH, Mohanty S, Mohanty P, Trivedi C, Morris EH, Santangeli P et al. Prevalence of right atrial non-pulmonary vein triggers in atrial fibrillation patients treated with thyroid hormone replacement therapy. *J Interv Card Electrophysiol* 2017;**49**:111–7.
278. Wang M, Cai S, Sun L, Zhao Q, Feng W. Safety and efficacy of early radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation complicated with amiodarone-induced thyrotoxicosis. *Cardiol J* 2016;**23**:416–21.
279. Mikhaylov EN, Orshanskaya VS, Lebedev AD, Szili-Torok T, Lebedev DS. Catheter ablation of paroxysmal atrial fibrillation in patients with previous amiodarone-induced hyperthyroidism: a case-control study. *J Cardiovasc Electrophysiol* 2013;**24**:888–93.
280. Diemberger I, Biffi M, Martignani C, Boriani G. From lead management to implanted patient management: indications to lead extraction in pacemaker and cardioverter-defibrillator systems. *Expert Rev Med Devices* 2011;**8**:235–55.
281. Mazzotti A, Biffi M, Massaro G, Martignani C, Ziacchi M, Bacchi Reggiani ML et al. From lead management to implanted patient management: systematic review and meta-analysis of the last 15 years of experience in lead extraction. *Expert Rev Med Devices* 2013;**10**:551–73.
282. Habib A, Le KY, Baddour LM, Friedman PA, Hayes DL, Lohse CM et al.; Mayo Cardiovascular Infections Study Group. Predictors of mortality in patients with cardiovascular implantable electronic device infections. *Am J Cardiol* 2013;**111**:874–9.
283. De Maria E, Diemberger I, Vassallo PL, Pastore M, Giannotti F, Ronconi C et al. Prevention of infections in cardiovascular implantable electronic devices beyond the antibiotic agent. *J Cardiovasc Med (Hagerstown)* 2014;**15**:554–64.
284. Nielsen JC, Gerdes JC, Varma N. Infected cardiac-implantable electronic devices: prevention, diagnosis, and treatment. *Eur Heart J* 2015;**36**:2484–90.
285. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying-prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;**40**:373–83.
286. Boriani G, Berti E, Belotti LM, Biffi M, De Palma R, Malavasi VL et al.; RERAL (Registry of Emilia Romagna on Arrhythmia Interventions) Investigators. Cardiac device therapy in patients with left ventricular dysfunction and heart failure: 'real-world' data on long-term outcomes (mortality, hospitalizations, days alive and out of hospital). *Eur J Heart Fail* 2016;**18**:693–702.
287. Echouffo-Tcheugui JB, Masoudi FA, Bao H, Spatz ES, Fonarow GC. Diabetes and outcomes of cardiac resynchronization with implantable cardioverter defibrillator therapy in older patients with heart failure. *Circ Arrhythm Electrophysiol* 2016;**9**:e004132.
288. Boriani G. The impact of diabetes and comorbidities on the outcome of heart failure patients treated with cardiac resynchronization therapy: implications for patient management. *Circ Arrhythm Electrophysiol* 2016;**9**:e004463.
289. Sun H, Guan Y, Wang L, Zhao Y, Lv H, Bi X et al. Influence of diabetes on cardiac resynchronization therapy in heart failure patients: a meta-analysis. *BMC Cardiovasc Disord* 2015;**15**:25.
290. Hoppe UC, Freemantle N, Cleland JG, Marijanowski M, Erdmann E. Effect of cardiac resynchronization on morbidity and mortality of diabetic patients with severe heart failure. *Diabetes Care* 2007;**30**:722–4.
291. Earley A, Persson R, Garlitski AC, Balk EM, Uhlig K. Effectiveness of implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in subgroups: a systematic review. *Ann Intern Med* 2014;**160**:111–121.
292. Shahreyar M, Mupiddi V, Choudhuri I, Sra J, Tajik AJ, Jahangir A. Implantable cardioverter defibrillators in diabetics: efficacy and safety in patients at risk of sudden cardiac death. *Expert Rev Cardiovasc Ther* 2015;**13**:897–906.
293. Braunschweig F, Boriani G, Bauer A, Hatala R, Herrmann-Lingen C, Kautzner J et al. Management of patients receiving implantable cardiac defibrillator shocks: recommendations for acute and long-term patient management. *Europace* 2010;**12**:1673–90.
294. Boriani G, Savelieva I, Dan GA, Deharo JC, Ferro C, Israel CW et al. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making—a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. *Europace* 2015;**17**:1169–96.
295. Roffi M, Cattaneo F, Brandle M. Thyrotoxicosis and the cardiovascular system. *Minerva Endocrinol* 2005;**30**:47–58.
296. Marketou ME, Simantirakis EN, Manios EG, Vardas PE. Electrical storm due to amiodarone induced thyrotoxicosis in a young adult with dilated cardiomyopathy: thyroidectomy as the treatment of choice. *Pacing Clin Electrophysiol* 2001;**24**:1827–8.
297. Sharma AK, Vegh EM, Orencole M, Miller A, Blendea D, Moore S et al. Association of hypothyroidism with adverse events in patients with heart failure receiving cardiac resynchronization therapy. *Am J Cardiol* 2015;**115**:1249–53.
298. Chen S, Shauer A, Zwas DR, Lotan C, Keren A, Gotsman I. The effect of thyroid function on clinical outcome in patients with heart failure. *Eur J Heart Fail* 2014;**16**:217–26.
299. Study of the effects of intravenous exenatide on cardiac repolarization. ClinicalTrials.gov Identifier: NCT 02650479.
300. Haugaard SB, Sajadeh A. The Effect of liraglutide on the treatment of coronary artery disease and type 2 diabetes (AddHope2). ClinicalTrials.gov Identifier: NCT 01595789.
301. Rosenqvist M, Giesecke P. Thumb-ECG ambulant screening for atrial fibrillation in patients treated for hyperthyroidism (TAMBOURINE) (TAMBOURINE). ClinicalTrials.gov Identifier: NCT 01945229.
302. Giesecke P. Is a Low Thyreotropin level predictive of recurrent arrhythmia after catheter ablative surgery? (TABLAS). ClinicalTrials.gov Identifier: NCT 01789541.
303. Kerstens MN, Links TP, Wietasch GJ. Phenoxybenzamine versus doxazosin in PCC patients (PRESCRIPT). ClinicalTrials.gov Identifier: NCT 01379898.
304. Zhang B. Assessment of BIM23B065, given as repeated subcutaneous injection in subjects with acromegaly (DOPAACRO 002). ClinicalTrials.gov Identifier: NCT03045302.